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ABSTRACT
Gastrointestinal symptoms and impaired quality of life caused by irritable bowel syndrome 
(IBS) aff ect up to one fi ft h of the adult population worldwide. IBS is reckoned as a multifactorial 
condition with dysregulation at the central and peripheral level, but the exact aetiological and 
pathophysiological factors of IBS are incompletely understood. No single deviance has been identifi ed 
in IBS microbiota, but a growing body of evidence indicates the involvement of the microbiota 
in the pathophysiology of the condition. Clinical studies also suggest that supplementation with 
certain probiotics may be benefi cial in IBS, but there is not enough evidence to make general 
recommendations. Th e aim of this thesis was to investigate microbiota- and mucosa-associated 
pathophysiological factors of IBS, and to evaluate the long-term eff ects of multispecies probiotic 
supplementation on symptoms, quality of life, intestinal microbiota and systemic infl ammatory 
markers in IBS.
Th e intestinal microbiota composition in IBS patients and healthy control subjects was 
analysed by quantitative polymerase chain reaction (qPCR). Microbiota composition was found 
to be altered in IBS, as shown by signifi cantly lower counts for the Clostridium coccoides and the 
Bifi dobacterium catenulatum groups. Quantitative diff erences also appeared in subgroup analysis 
based on the predominant bowel habit: diarrhoea patients harboured signifi cantly lower numbers 
of Lactobacillus spp. than the constipation-predominant patients, while higher counts for Veillonella 
spp. were detected in constipation-predominant patients compared to healthy controls. Analysis 
of mucosal biopsies by a high-throughput metabolomic approach revealed multiple diff erences 
between IBS patients and controls. Th e most prominent fi nding was an upregulation of specifi c 
lipid species, principally lysophosphatidylcholines and ceramides, in IBS. 
Th e eff ects of multispecies probiotic supplementation with Lactobacillus rhamnosus GG, 
Lactobacillus rhamnosus Lc705, Propionibacterium freudenreichii subsp. shermanii JS, and 
Bifi dobacterium breve Bb99 or Bifi dobacterium animalis subsp. lactis Bb12 was evaluated in two 
long-term, randomised, double-blind, placebo-controlled trials. Compared to placebo, the probiotic 
supplementation signifi cantly reduced the total symptoms of IBS. No eff ects on bowel habit were 
seen. Health-related quality of life (HRQOL) is reduced in patients with IBS in comparison with 
the Finnish population on the whole. Th e probiotic supplementation improved one IBS-specifi c 
domain of quality of life (bowel symptoms), whereas no eff ects were seen on other IBS-specifi c 
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domains or generic HRQOL. Th e probiotics had no major eff ects on the predominant microbiota 
as measured by qPCR, but a microarray-based analysis conducted on a subgroup of patients 
suggested that the probiotic consumption was associated with a stabilisation of the microbiota. 
No eff ects on serum sensitive C-reactive protein (CRP) or serum cytokines were detected.
Taken together, alterations in the microbiota composition and in the mucosal metabolite 
profi le are potential pathophysiological factors of IBS. Multispecies probiotic supplementation 
alleviated the gastrointestinal symptoms of IBS. Th e probiotic supplementation improved the 
bowel symptoms domain of HRQOL, while no eff ects were seen on generic measures of quality 
of life. Probiotic supplementation in IBS is associated with a stabilisation of microbiota, but it 
does not infl uence systemic infl ammatory markers.
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1. INTRODUCTION
Irritable bowel syndrome (IBS) is a major cause of abdominal discomfort and gut dysfunction 
worldwide. Th e global prevalence of IBS is estimated to be between 10% and 20% of the adult 
population (for review, see Longstreth et al. 2006), which shows IBS to be the most frequent 
diagnosis in gastroenterology (Russo et al. 1999). IBS is a benign, non-life threatening condition, 
but its social and economic burden is signifi cant. From the patient-perspective, IBS is a painful and 
distressing syndrome that impairs quality of life (Hahn et al. 1999; Gralnek et al. 2000; Amouretti 
et al. 2006), and increased health-care service utilisation and absence from work by IBS patients 
account for the considerable fi nancial costs of the condition (for review, see Maxion-Bergemann 
et al. 2006).
Th e current view on IBS and other functional gastrointestinal (GI) disorders is that they are 
complex, biopsychosocial and multifactorial conditions with dysregulation at both the central and 
peripheral level (for review, see Drossman 2006). Th e precise aetiology and pathophysiology of IBS 
remain unexplained, but altered gut motility, enhanced visceral sensation, previous gastroenteritis, 
mucosal infl ammation, abnormal brain-gut communication, psychosocial factors, food intolerance, 
intestinal microbiota and genetics are identifi ed as key factors. Up-to-date management of IBS is 
based on a good physician-patient relationship, lifestyle recommendations and pharmacotherapy 
when required. However, many of the routinely used medications in IBS have only limited evidence 
for their effi  cacy, safety and tolerability (for review, see Heading et al. 2006), and almost every 
second patient taking prescribed medication considers it ineff ective (Dapoigny et al. 2004). 
Clinical trials suggest that certain probiotic bacteria or combinations of bacteria may have 
benefi cial eff ects on the IBS symptom complex (Nobaek et al. 2000; Niedzielin et al. 2001; Kim 
et al. 2003; Kim et al. 2005b; O’Mahony et al. 2005; Whorwell et al. 2006). Th ough evidence is 
promising, no general recommendations on the use of probiotics in IBS can be given as yet. In 
addition to further clinical trials, data on the mechanisms of action of probiotics in IBS are needed. 
Th e safety of therapy is of particular importance in a non-life threatening condition such as IBS. 
Recently, the withdrawal and restricted reintroduction in the US of two serotonergic IBS medicines, 
alosetron and tegaserod (for review, see Longstreth et al. 2006), has triggered a useful discussion 
on the safety aspects of IBS therapy. Probiotics are considered safe (for review, see Borriello et al. 
2003), and if future scientifi c data is able to substantiate their effi  cacy in IBS, they could be one 
treatment option to be considered.
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Th e purpose of the present study was to investigate the pathophysiological factors involved 
in the development of IBS and to evaluate the eff ects of probiotic supplementation in IBS. Th e 
intestinal microbiota composition and the mucosal metabolic profi le of IBS patients and healthy 
control subjects were compared.  Additionally, the eff ects of multispecies probiotic supplementation 
on symptoms, quality of life, intestinal microbiota composition and stability, and systemic 
infl ammatory markers in IBS were evaluated in long-term randomised, controlled trials.
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2. REVIEW OF THE LITERATURE
2.1 Irritable bowel syndrome 
2.1.1 Deﬁ nition and disease description 
IBS is defi ned as a functional bowel disorder in which abdominal pain or discomfort is associated 
with defecation or a change in bowel habit, and with features of disordered defecation (for review, 
see Longstreth et al. 2006). IBS belongs to the group of functional bowel disorders, which also 
includes functional bloating, functional constipation, functional diarrhoea and unspecifi ed 
functional bowel disorder. Functional bowel disorders are one of a total of eight major domains 
in the large diagnostic group of functional gastrointestinal disorders (Table 1). 
Table 1. The classiﬁ cation of functional gastrointestinal disorders according to the Rome III  
 criteria (for review, see Drossman 2006).
Functional gastrointestinal disorders
A. Functional oesophageal disorders
B. Functional gastroduodenal disorders
C. Functional bowel disorders
D. Functional abdominal pain syndrome
E. Functional gallbladder and Sphincter of Oddi (SO) disorders
F.  Functional anorectal disorders
G. Functional disorders: neonates and toddlers
H. Functional disorders: children and adolescents
Th e main feature of IBS is recurrent abdominal pain or discomfort that is associated with disordered 
defection and changes in bowel habit (for review, see Longstreth et al. 2006). Other symptoms 
characteristic for IBS and classifi ed as supportive symptoms include: abnormal stool frequency 
(≤3 stools/week or >3/day), abnormal stool form, defecation straining, urgency, incomplete bowel 
movements, mucus and bloating. Based on the supportive symptoms, IBS can be subdivided 
into IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C) and IBS with alternating bowel 
habit (IBS-A). Th e syndrome is chronic in nature, but associated with a good prognosis and no 
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increased mortality in long-term follow-up (Owens et al. 1995). Bowel habit in one patient oft en 
changes over time, and symptoms are typically fl uctuating (Mearin et al. 2004). Extraintestinal 
comorbidity is oft en associated with IBS since specifi c disorders, such as headache, food allergy, 
musculoskeletal complaints, fi bromyalgia and mood disorders, oft en overlap with IBS (Sperber et 
al. 1999; Vandvik et al. 2006; Hillilä et al. 2007). Moreover, IBS oft en coexists with other functional 
GI disorders (for review, see Whitehead et al. 2002). A recent study, however, indicates that there 
are no specifi c comorbid disorders that are associated with IBS (Whitehead et al. 2007). Instead, 
a general increase of disease incidence may be typical of IBS since the disorders most common 
in the general population (i.e. bacterial and viral infections, stroke) are the ones most common 
in IBS, too. Excess comorbidity may be due to hypervigilance in noticing somatic sensations and 
to having a lower threshold for consulting a physician.
2.1.2 Epidemiology
Irritable bowel syndrome was the seventh most prevalent diagnosis amongst all physicians in the 
US based on data collected in the 1970s and 80s (Everhart and Renault 1991). Similarly, more 
recent data from the US show that IBS accounts for 19% of diagnoses made by GI specialists, and 
is therefore the most common diagnosis in gastroenterology (Russo et al. 1999). Th e worldwide 
prevalence of IBS among adults is estimated to be 10-20% (Österberg et al. 2000; Th ompson et 
al. 2002; Hungin et al. 2003; Hungin et al. 2005). Th ough the majority of prevalence fi gures are 
from Western populations, increasing data reveal that the syndrome is at least as prevalent in 
such non-Western societies as China, South Korea, India and Malaysia (Jain et al. 1991; Tan et 
al. 2003; Xiong et al. 2004; Park et al. 2007). It should, on the other hand, be taken into account 
that at least the urban areas of these countries are rapidly Westernising. Th e prevalence of IBS on 
the African continent is poorly known, but data from Kenya and Nigeria show prevalence fi gures 
between 8% and 33% (Lule and Amayo 2002; Okeke et al. 2005; Ladep et al. 2007). It is obvious 
that the defi nitions, diagnostic criteria and questionnaires employed infl uence the prevalence 
rates of IBS, and some studies have consequently shown prevalence fi gures below 10% (Kay et 
al. 1994; Andrews et al. 2005). When various diagnostic criteria were compared in a random 
adult population in Finland, the prevalence of IBS by Manning 2 or Manning 3 (Manning et al. 
1978), Rome I (Th ompson et al. 1992) and Rome II (Th ompson et al. 1999) criteria was 16.2%, 
9.7%, 5.6% and 5.1%, respectively (Hillilä and Färkkilä 2004b). Th e precise incidence of IBS is 
poorly known, but the incidence of the clinical diagnosis is estimated at 0.2% per year for each 
decade between 20 and 94 years (for review, see Camilleri et al. 2002b). Th is may, on the other 
hand, be an underestimate of the true incidence, since only one in four IBS patients consults a 
physician (Talley et al. 1995).
In general, there is a clear female predominance among IBS patients (Österberg et al. 2000; 
Th ompson et al. 2002; Hungin et al. 2003; Hungin et al. 2005). Among those seeking health care 
services, women lead men in IBS diagnoses by a ratio of 2-4:1, whereas the distribution seems 
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to be less than 2:1 in prevalence data based on community surveys (for review, see Chang and 
Heitkemper 2002). Possible explanations for the gender diff erences include social and cultural 
issues, such as health care seeking behaviour, and sex-related physiological diff erences in bowel 
function and pain sensitivity. In contrast to Western societies, IBS seems to be noticeably more 
predominant among men than women in India (Jain et al. 1991). Th is has been suggested to 
refl ect cultural diff erences in health care seeking and accessibility (for review, see Chang and 
Heitkemper 2002). IBS can aff ect people at any age, but the condition is most commonly diagnosed 
between ages 20 and 40, whereas organic GI diseases predominate in those over 60 (for review, 
see Bennett and Talley 2002). Irritable bowel syndrome may also appear in childhood, but data 
on prevalence are scarce. In some reports, IBS has been diagnosed in 6-14% of school children 
(Hyams et al. 1996) and 22%-45% of children aged 4-18 years presenting to tertiary care clinics 
(Walker et al. 2004; Caplan et al. 2005).
To summarise, the worldwide prevalence of IBS is about 10% to 20%, depending on 
the diagnostic criteria applied. The condition is more common in women than in 
men, and it is typically diagnosed in young adults. 
2.1.3 Social and economic impact
Although IBS is non life-threatening, it is a painful, bothersome and distressing condition that 
interferes with daily life and creates considerable direct and indirect costs to society. Health-
related quality of life (HRQOL) is signifi cantly lower in subjects with IBS compared to healthy 
controls (Hahn et al. 1999; Gralnek et al. 2000; Akehurst et al. 2002; Amouretti et al. 2006). 
Overall, it appears that the more severe the IBS, and especially abdominal pain, the more impaired 
the quality of life (Coffi  n et al. 2004; Amouretti et al. 2006). Non-consulting IBS patients have 
better quality of life than health care consulting patients (Ringström et al. 2007), even though 
the former group also has slightly impaired HRQOL compared to healthy controls (Koloski et 
al. 2000). In comparison with other GI conditions, quality of life in IBS is signifi cantly poorer 
than in those with refl ux disease (Gralnek et al. 2000; Frank et al. 2002). Scores are also lower 
in selected domains compared to patients with diabetes, renal failure, asthma and migraine. 
In general, compromised HRQOL appears to be a common observation in patients with GI 
complaints, and data from the Medical Outcomes Study show that this group of patients scored 
amongst the lowest of all conditions studied, including conditions with high mortality such as 
heart failure (Stewart et al. 1989). It should, nevertheless, be kept in mind that symptom severity 
is a strong predictor of HRQOL in IBS, and patients with mild IBS are thus not likely to score as 
low as subjects with serious diseases. 
Th e economic impact of IBS arises from the direct consumption of health care resources 
as well as the loss of productivity by subjects suff ering from IBS. Total health care utilisation 
and, as a result, direct health care costs are higher amongst subjects with IBS than in control 
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populations without IBS (Levy et al. 2001b; Akehurst et al. 2002), even though the majority of 
IBS patients do not seek medical help (Talley et al. 1995). A majority of the excess costs result 
from medical care not directly related to GI problems. A recent review estimates that the total 
direct costs per IBS patient per year is between USD 348 and USD 8,750, which correlates to a 
1.1- to 6-fold higher cost compared to matched non-IBS control groups (Maxion-Bergemann 
et al. 2006). Compared to other GI problems, the costs per patient for IBS are lower than for 
infl ammatory bowel diseases (IBD), but of the same magnitude as in gastro-oesophageal refl ux 
disease (Levy et al. 2001b). Th e economic burden of IBS is partly due to loss of productivity: the 
average annual number of days off  work due to IBS is calculated to be between 8.5 and 21.6 in the 
US and UK (for review, see Maxion-Bergemann et al. 2006). For comparison, this corresponds 
to an approximately 3-fold higher risk for absence from work in a US IBS population compared 
to non-IBS patients (Drossman et al. 1993).
Taken together, health-related quality of life is clearly impaired in IBS. The severity 
of abdominal symptoms correlates positively with HRQOL reduction. IBS causes 
considerable costs to society in the form of health care utilisation and absence 
from work.
2.1.4 Diagnosis
Th e diagnosis of IBS is based on identifi cation of symptoms consistent with the condition and 
on case-by-case evaluated exclusion of other diseases with similar clinical features (for review, 
see Longstreth et al. 2006). Th e fi rst symptom-based diagnostic criteria were published by 
Manning in 1978 (Manning et al. 1978), and they have been widely utilised in epidemiological 
and clinical studies. Th e multinational Rome working committee published its fi rst criteria for 
IBS diagnosis in 1989 (Th ompson et al. 1989), and has since then regularly published updated 
versions (Th ompson et al. 1992; Th ompson et al. 1999). Th e most current version, the Rome 
III criteria, were issued in 2006 (for review, see Longstreth et al. 2006). Th e Rome I, II and III 
criteria appear in Table 2.
Generally, few diagnostic tests are required for subjects who fulfi l the symptom-based 
criteria for IBS and show no alarm signs (for review, see Longstreth et al. 2006). In this patient 
group, further testing usually provides little or no incremental value, and organic GI disease is 
rarely identifi ed aft er symptom-based diagnosis of IBS (for review, see Cash et al. 2002). In cases 
where further investigations are considered justifi ed, these should be based on the patient’s age, 
duration and severity of symptoms, psychosocial factors, alarm features and family history of 
GI disease. Fever, GI bleeding, weight loss, anaemia, family history of colon cancer and onset of 
symptoms in an older patient are considered alarm features that require closer investigation. Th e 
main diseases to be excluded in diff erential diagnosis are IBD in the young and colon cancer in 
older subjects in the Western world, and malabsorption or enteric pathogen infections in non-
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Western populations (for review, see Camilleri et al. 2002b). Th e exclusion of coeliac sprue by 
serology and endoscopic biopsy is recommended, at least in individuals with diarrhoea (Spiegel 
et al. 2004). Furthermore, microscopic colitis can present with IBS-like symptoms and should 
consequently be excluded (Niemelä 2001). All in all, a symptom-based diagnosis of IBS is a “safe 
diagnosis”, where most subjects continue to be symptomatic during follow-up, but where the 
diagnosis is unlikely to be altered with time (Owens et al. 1995). 
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Table 2.  The Rome I, II and III criteria for IBS.
Rome I criteria (Thompson et al. 1992)
At least three months continuous or recurrent symptoms of:
1. Abdominal pain or discomfort which is:
Relieved with defecation
and/or associated with a change in frequency of stool
and/or associated with a change in consistency of stool, and
2. Two or more of the following, at least a quarter of occasions or days: altered stool frequency; 
altered stool form (lumpy/hard or loose/watery stool); altered stool passage (straining, urgency 
or feeling of incomplete evacuation); passage of mucus; and bloating or feeling of abdominal 
distension.
Rome II criteria (Thompson et al. 1999)
At least 12 weeks, which need not be consecutive, in the preceding 12 months of abdominal 
discomfort or pain that has two of three features:
1. Relieved with defecation; and/or
2. Onset associated with a change in frequency of stool; and/or
3. Onset associated with a change in form (appearance) of stool
The following symptoms cumulatively support the diagnosis of IBS: abnormal stool frequency; 
abnormal stool form (lumpy/hard or loose/watery stool); abnormal stool passage (straining, 
urgency or feeling of incomplete evacuation); passage of mucus; and bloating or feeling of 
abdominal distension.
Rome III criteria* (Longstreth et al. 2006)
Recurrent abdominal pain or discomfort** at least 3 days per month in the last 3 months 
associated with 2 or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool
3. Onset associated with a change in form (appearance) of stool
* Criteria fulﬁ lled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
** Discomfort means an uncomfortable sensation not described as pain. In pathophysiology 
research and clinical trials, a pain/discomfort frequency of at least 2 days a week during screening 
evaluation for subject eligibility.
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2.1.5 Pathophysiology
IBS is seen as a complex biopsychosocial condition in which a number of major mechanisms at 
the central and peripheral level interact (for review, see Drossman 2006). Th ese include altered 
gut motility, enhanced visceral sensation, low-grade mucosal infl ammation, abnormal brain-gut 
communication, psychosocial factors, food intolerance, intestinal microbiota and genetics (Figure 1). 
Th e contribution of microbiota to the pathophysiology of IBS will be discussed separately under 
Section 2.2. Th e prominence of any particular factor may vary from patient to patient.
Figure 1.  Biopsychosocial model of IBS depicting the relationship between pathophysiology, 
symptom expression and clinical outcome (modiﬁ ed from Drossman 2006).
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Abnormal motility
A variety of motor abnormalities have been described throughout the GI tract in IBS. Several 
distinct patterns of motility that vary in their intensity, type and location normally occur within 
the human GI tract. Overall, patients and healthy controls diff er in quantitative, rather than 
qualitative, aspects of these motility patterns. In comparison with controls, IBS patients appear 
to have a delayed gastric emptying (Evans et al. 1997; Caballero-Plasencia et al. 1999), though 
not all studies support this (Acharya et al. 1983). Small bowel motility is altered in IBS in several 
ways: typical fi ndings include a shorter duration of postprandial motor activity combined with 
episodes of clustered, recurring contractions correlating with abdominal pain (Kellow et al. 1990). 
Furthermore, abnormal duodenal pressure waves that correlate with symptom severity have been 
observed in IBS-D (Simrén et al. 2000). Small bowel transit time is signifi cantly shorter in IBS-D 
and longer in IBS-C, compared to controls (Cann et al. 1983). 
Both in the small and large bowel, IBS patients show an exaggerated response to a range of 
provocative stimuli. For instance, hypermotility of the small bowel in IBS patients is seen aft er 
infusions of cholecystokinin, a fatty meal, or ileal distension (Kellow et al. 1988), and colonic 
motor activity is exaggerated aft er a meal, an anger stressor or cholecystokinin (Welgan et al. 
1988; Rogers et al. 1989; Chey et al. 2001). During cholecystokinin administration, abdominal 
pain coincided with >90% of the large-bowel high-amplitude contractions, suggesting that 
abnormalities in these vigorous colonic contractions may be one of the causes of pain (Chey et 
al. 2001). Basal non-stimulated large-bowel motility parameters, such as the myoelectric activity 
(Bueno et al. 1980) and sigmoid-colonic motor activity (Chey et al. 2001; Houghton et al. 2007a), 
also appear to be altered in IBS. Similarly to the small bowel transit times, the whole-gut and 
colonic transit times are shortened in IBS-D and prolonged in IBS-C (Cann et al. 1983; Chey et 
al. 2001; Dunlop et al. 2005). Besides aberrant gut transit, an impaired transit and tolerance of 
intestinal gas is suggested to be typical for IBS (Serra et al. 2001). Th is may be a consequence of 
altered gut motor function. 
Although abnormal GI motor patterns are frequently observed in IBS, the mechanism 
behind such dysmotility is largely unknown. It has been proposed that disordered functioning 
of the enteric nervous system and serotonin signalling may be involved. Th is is corroborated by 
abnormal serotonin levels and turnover in IBS (Coates et al. 2004; Dunlop et al. 2005) and by 
the observation that endogenous serotonin (5-hydroxytryptamine, 5-HT) concentrations clearly 
correlate with the colonic activity index in IBS (Houghton et al. 2007a). 
To summarise, various gut motor disturbances are present throughout the GI tract 
in IBS patients. These are likely to be important in determining the bowel habit, but 
their relevance in the generation of other GI symptoms is not as clear. The causes 
underlying these dysmotility patterns are thought to lie in alterations in the function 
of the enteric nervous system and in serotonin signalling.
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Enhanced visceral perception 
Visceral hypersensitivity, defi ned as an increased sensation in response to intestinal stimuli, is one 
of the most commonly found hallmarks of IBS and other functional gastrointestinal disorders 
(for review, see Delvaux 2002). Th e phenomenon is a frequent, but not constant, fi nding in IBS 
patients. Evidence of visceral hypersensitivity in humans is principally based on barostat tests that 
measure the pain sensation caused by gastrointestinal balloon distension. In these study settings, 
IBS patients perceive the fi rst sensation of pain at lower volumes or pressures than healthy controls 
or display increased pain scores for a specifi c stimulus (Whitehead et al. 1990; Kilkens et al. 2005; 
Nozu et al. 2006; Zuo et al. 2006; Wilder-Smith and Robert-Yap 2007). Furthermore, visceral 
hypersensitivity in IBS patients and controls is diff erent with regard to external stimuli: duodenal 
lipid infusion or stress enhances the gut sensitivity to a greater extent in IBS patients compared 
to healthy subjects (Simrén et al. 2001a; Posserud et al. 2004). As in the case of dysmotility, 
visceral hypersensitivity in IBS is not limited to the colon, and it should rather be considered 
as a generalised sensitisation of the GI tract (Trimble et al. 1995). Sensory thresholds may be 
interrelated with bowel habits, and evidence suggests that diarrhoea-predominant patients are 
more sensitive to distension compared with healthy controls, while patients with constipation 
tendency are equally or less sensitive compared with controls (Prior et al. 1990b; Zar et al. 2006; 
Zuo et al. 2006). Symptom type and intensity do not distinct hypersensitive and normosensitive 
IBS patients: subjects with enhanced visceral perception present comparable symptoms to those 
with normal sensitivity level (Kuiken et al. 2005). Th e threshold for somatic pain in IBS patients 
has been considered similar or even higher compared to healthy controls (Whitehead et al. 
1990; Accarino et al. 1995; Iovino et al. 2006), but but there is also current data to the contrary 
(Wilder-Smith and Robert-Yap 2007).
Th e exact cause behind the enhanced visceral pain perception in IBS remains unknown, 
but studies point out that defects at both the peripheral and central level contribute to the 
phenomenon. Atypical gut parietal mechanoreceptors, possibly sensitised due to low-grade 
infl ammation, may be key players. Indeed, mechanical balloon distension results in lower pain 
thresholds in IBS, whereas unspecifi c electrical stimulation of the receptors does not distinguish 
between cases and controls (Accarino et al. 1995). Based on studies using specifi c nitric oxide 
synthase inhibitors, recent data also advocate a role for intestinal nitric oxide in the development 
of visceral hypersensitivity in IBS (Kuiken et al. 2006). Mucosal mast-cell mediators histamine 
and tryptase from IBS patients are able to excite rat nociceptive visceral sensory nerves, while 
mediators from healthy volunteers are unable to do this, suggesting a role for mast cells in the 
occurrence of visceral sensitivity (Barbara et al. 2007). In addition to nitric oxide and mast cell 
mediators, prostaglandin E2 is also a potent modulator of intestinal sensitivity (Haupt et al. 2000). 
Central processing of visceral stimuli appears to be altered in IBS, as shown by brain imaging 
studies where diff erent brain areas involved in pain processing are activated in IBS patients vs. 
controls following painful stimuli (Silverman et al. 1997; Bonaz et al. 2002; Song et al. 2006). 
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Taken together, visceral hypersensitivity is a key feature of IBS. Hypersensitivity 
occurs throughout the GI tract, whereas the threshold for somatic pain appears to be 
unaltered in IBS. The sensitivity defects are most likely a result of the sensitisation 
of nerve afferent pathways in the GI tract as well as unusual brain processing of 
nociceptive information.
Gastroenteritis and low-grade inflammation
Th e term “post-dysenteric irritable bowel syndrome” was introduced nearly 50 years ago by 
Chaudhary and Truelove (1962), who described that a subset of patients with “irritable colon 
syndrome” dated the onset of their symptoms to an attack of GI infection. Today, prospective 
studies show a 4%-31% incidence of post-infectious IBS (PI-IBS) following bacterial gastroenteritis 
(for review, see Spiller 2007). Th e relative risk for developing PI-IBS aft er acute gastroenteritis 
is estimated to be approximately 12 (Rodríguez and Ruigómez 1999). Most patients do not, 
however, develop PI-IBS, and the prevalence of IBS is not elevated in countries with high rates of 
enteric infection, which indicates that a range of risk factors are associated with PI-IBS. Factors 
associated with increased vulnerability for post-infectious IBS include a longer duration of the 
initial diarrhoeal disease (Neal et al. 1997; Wang et al. 2004), female gender (Neal et al. 1997; 
Gwee et al. 1999) and psychological factors, e.g. depression and the presence of adverse life events 
in the previous three months (Gwee et al. 1999; Dunlop et al. 2003b). An age of over 60 years, in 
contrast, correlates with a protective eff ect against developing PI-IBS (Neal et al. 1997). Besides 
gastroenteritis, the use of antimicrobials for GI infection or other conditions also serves as an 
independent risk factor for developing functional bowel symptoms (Maxwell et al. 2002).
Even though IBS patients have no identifi able infl ammation on routine inspection of intestinal 
biopsies, there is an increasing amount of data showing that both post-infectious and unselected 
IBS patients display a low-grade mucosal infl ammation (Table 3). An array of immunological cells 
and markers have been examined, and the levels of lymphocytes, mast cells and enterochromaffi  n 
cells are repeatedly found to be altered in the mucosa of IBS patients. Moreover, evidence of 
systemic immune activation is accumulating, as elevated levels of plasma pro-infl ammatory 
interleukin (IL)-6 and IL-8 have been observed in IBS (Dinan et al. 2006). Peripheral blood 
mononuclear cells (PBMCs) of IBS patients also produce higher amounts of tumour necrosis 
factor-α, IL-1ß, IL-6 and IL-12 in vitro than cells from healthy controls (O’Mahony et al. 2005; 
Liebregts et al. 2007b). Th ese fi ndings are supported by genotyping studies indicating that IBS 
patients are predisposed towards a pro-infl ammatory cytokine profi le (Gonsalkorale et al. 2003; 
van der Veek et al. 2005). Gut barrier function is tightly interlinked with infl ammation since 
permeability is increased both by infl ammatory cytokines and by bacterial gastroenteritis (Chavez 
et al. 1999; Spiller et al. 2000). In parallel with studies on cytokine imbalance in IBS, evidence 
is mounting that there may be an IBS subgroup with increased mucosal permeability (Spiller et 
al. 2000; Marshall et al. 2004; Dunlop et al. 2006).
Animal studies have given insight into the mechanisms by which prior infl ammation may 
25
provide ongoing neuromuscular dysfunction in the gut. While an immunological response 
is initially required for the induction of neuromuscular changes, it is not necessary for the 
maintenance of these changes aft er an infection (for review, see Khan and Collins 2006). Instead, 
the state of persistently altered GI physiology, observed for instance in IBS, is actively maintained 
by the production of mediators like transforming growth factor-ß and prostaglandin-E2 by 
intestinal muscle cells (Barbara et al. 2001; Akiho et al. 2005). Th e involvement of infl ammation 
in neuromotor function is also supported by the fi nding that, both in normal and in infl amed 
mucosa, immunocytes lie in intimate contact with nerve fi bres, providing an anatomical basis for a 
functional interplay between immune cells and the enteric nervous system (Stead et al. 1987).
To summarise, gastroenteritis is one recognised risk factor for developing IBS. 
Routine inspection does not show mucosal inﬂ ammation in IBS, but speciﬁ c analysis 
of particular immune cells and markers reveals subtle inﬂ ammatory alterations in 
patients. Especially gut lymphocytes, mast cells and enterochromafﬁ n cells are 
frequently elevated in IBS. Studies in animal models indicate a causal relationship 
between mucosal inﬂ ammation, altered GI motor function and visceral hypersensitivity, 
with several molecular mechanisms involved in the phenomenon.
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Brain-gut communication
Perturbations in the brain-gut axis are increasingly recognised as underlying pathophysiological 
factors in functional GI disorders. Th e brain-gut axis is considered a model describing the complex 
bidirectional neural pathways connecting the brain with the gut neuroendocrine centres, the enteric 
nervous system and the immune system (for review, see Aziz and Th ompson 1998). Disturbed 
brain-gut communication is not an independent pathophysiological factor in IBS, as the brain-
gut axis is the key regulator of e.g. gut motor activity and visceral perception, both known to be 
changed in IBS. Altered communication between the central nervous system (CNS) and the gut 
is thus tightly interlinked with other established pathophysiological phenomena in IBS.
Overall, brain-gut interactions play an important role in the regulation of many vital 
functions both in health and in disease. Digestive functions, including motility, secretion, 
mucosal transport and blood fl ow are coordinated by the CNS in a top-down manner (for review, 
see Costa and Brookes 1994). Conversely, signals from the gut play a role in refl ex regulation 
and pain perception in a bottom-up manner (for review, see Randich and Gebhart 1992). Th e 
CNS functions as a “fi lter” with regard to the perception of peripheral aff erent signals, and the 
brain-gut communication is for the most part not consciously perceived: only very few of the 
signals reaching the brainstem and thalamus are consciously perceived in the cortex (Rosen et 
al. 1996). Th e brain-gut axis is stimulated by various stressors, as shown by the fact that acute 
intestinal infl ammation is associated with central sensitisation (Liebregts et al. 2007a), whereas 
psychological events alter gut function (Mönnikes et al. 1993; Nakade et al. 2007).
Symptoms of IBS are thought to be produced by primary alterations in the CNS, by primary 
alterations in the periphery, or by a combination of both. Evidence for central alterations in 
IBS comes from studies using functional brain imaging techniques where diff erent brain areas 
involved in pain processing are activated in IBS patients vs. controls following painful rectal 
stimuli (Silverman et al. 1997; Bonaz et al. 2002; Song et al. 2006). Moreover, IBS patients appear 
to have an altered processing of anticipated pain, since sham distension resulted in similarly 
low pain scores in IBS patients and healthy subjects, but a diff erential brain activation pattern 
(Song et al. 2006). Central processing may also distinguish between diff erent bowel habits, as 
demonstrated by lower parasympathetic tone and higher autonomic nervous system balance in 
constipation-predominant vs. diarrhoea-predominant patients (Heitkemper et al. 2001). Th e role 
of the central and the autonomic nervous system in IBS pathophysiology is supported by fi ndings 
of sleep disturbances, and especially an enhancement of rapid eye movement sleep in IBS (Orr et 
al. 1997). Studies presenting elevated levels of corticotropin-releasing and adrenocorticotropic 
hormones as well as alterations of the visceral perception in IBS patients following mental stress 
also point towards disturbed brain-gut interaction (Posserud et al. 2004).
Numerous neurotransmitters are involved in the regulation of the brain-gut axis. Amongst 
those, serotonin is of particular interest since its eff ects on gut motility, secretion and sensation 
as well as on cognition and mood make it of paramount relevance in IBS pathophysiology (for 
review, see Mawe et al. 2006). Acute lowering of serotonin synthesis reduces the threshold for 
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painful stimuli and induces a depression-like memory bias both in IBS patients and in control 
subjects, illustrating the essential role of serotonergic modulation in the brain-gut axis (Kilkens et 
al. 2004b). In contrast, increased 5-HT activity induced by citalopram is associated with enhanced 
aff ective memory performance biased towards positive words (Kilkens et al. 2005). Several 
elements of serotonin signalling are altered in IBS. Th e numbers of enterochromaffi  n cells (the 
source of 5-HT in the bowel) have been shown to be increased, especially in the post-infectious 
subgroup (Spiller et al. 2000; Dunlop et al. 2003b). Elevated plasma 5-HT concentrations have 
been observed in an unselected IBS population (Bearcroft  et al. 1998) and in post-infectious IBS 
(Dunlop et al. 2005), while the opposite is seen in constipation IBS (Dunlop et al. 2005). Moreover, 
decreased 5-HT levels and turnover, lower 5-HT transporter mRNA concentration, and increased 
expression of p11, a protein aff ecting serotonin metabolism, are shown in IBS (Coates et al. 2004; 
Dunlop et al. 2005; Camilleri et al. 2007). Another important group of molecules aff ecting the 
brain-gut are prostaglandins, which appear to exert their eff ects via peripheral mechanisms in 
the GI tract rather than via central mechanisms (Dajani et al. 2003).
Taken together, the brain-gut axis describes the complex and bidirectional interplay 
between the GI tract and the CNS. Several neurotransmitters, for instance serotonin, 
modulate the brain-gut interaction. Functional communication between the brain 
and the gut is crucial for a number of physiological events, including digestion 
and motility. IBS patients demonstrate alterations in peripheral signalling, central 
processing of signals and in serotonin metabolism, and these factors are believed 
to participate in symptom generation.
Psychosocial factors
Psychosocial factors are not believed to cause IBS, but they exert a strong infl uence on some 
patients. Psychological stress and emotions produce GI symptoms in almost all individuals, 
but IBS patients appear to be particularly susceptible to an exacerbation of symptoms by stress 
(Whitehead et al. 1992). IBS patients also consistently report more lifetime and daily stressful 
events than control groups (Whitehead et al. 1992; Locke et al. 2004). Psychological symptoms 
and comorbidity frequently exist in IBS, especially in those seeking health care. Commonly 
encountered conditions in these patients include depression, somatisation, anxiety disorder, 
panic disorder and phobic anxiety disorder (Walker et al. 1990; Solmaz et al. 2003). Importantly, 
psychological comorbidity may be restricted to consulting patients, since community surveys 
indicate that non-consulting individuals with IBS have psychosocial characteristics similar to the 
general population (Drossman et al. 1988). A recent prospective study also shows that psychosocial 
factors are independent risk factors for the development of IBS in a population previously not 
suff ering from the condition (Nicholl et al. 2007). Physical, sexual and psychological abuse as a 
child or as an adult is associated with the development of IBS, although the issue is somewhat 
controversial. Certain current studies report a positive association between abuse and IBS and 
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other functional GI disorders (Koloski et al. 2005; Perona et al. 2005), whereas others have been 
unable to confi rm the fi ndings (Hobbis et al. 2002). It has been proposed that the possible link 
between abuse and functional GI disorders may be in somatisation and a general tendency to 
report numerous bodily symptoms (Creed et al. 2005). It should be kept in mind that these 
phenomena appear to be more common at referral practices compared to primary care or non-
clinical settings (for review, see Drossman et al. 1995).
Th e impact of psychosocial factors lies in their eff ect on illness experience and treatment 
outcome. On one hand, psychosocial status is a determinant for health care seeking behaviour 
(Koloski et al. 2003; Ringström et al. 2007). A topical Finnish study, on the other hand, suggests 
that health care utilisation is associated with abdominal symptoms rather than psychiatric 
comorbidity (Hillilä et al. 2007). Psychosocial status is also associated with reduced illness 
behaviour and coping strategies (Jones et al. 2006). 
To summarise, psychological comorbidity and symptoms often coexist with IBS, 
particularly in referral centres. Psychosocial factors are not, however, considered 
to be a causative factor of IBS. In clinical practice, attention should be paid to 
psychosocial factors, since they are an important determinant of illness experience 
and treatment outcome.
Food intolerance
Food intolerance, sometimes also called food sensitivity, can be subdivided into food allergy, 
which is mediated by immunological mechanisms, and food intolerance mediated by non-
immunological mechanisms (for review, see Ortolani and Pastorello 2006). Both allergic and 
non-allergic adverse reactions to food have been suggested as playing a role in the development 
of IBS. A major proportion of IBS patients experience a postprandial worsening of GI symptoms 
(Ragnarsson and Bodemar 1998; Simrén et al. 2001b), and many patients report adverse reactions 
to certain food items as well as the use of exclusion diets (Dainese et al. 1999; Monsbakken et al. 
2006). Foods rich in carbohydrates and fat as well as coff ee, alcohol and spicy foods are frequently 
considered by IBS patients to be symptom-provoking (Simrén et al. 2001b). On the other hand, 
perceived food intolerance is not a phenomenon limited to IBS patients since approximately 
one fi ft h of the UK population consider themselves food intolerant, though only one to two 
percent get a positive reaction in a double-blind placebo-controlled food challenge (Young et al. 
1994). Th e reason for the perceived food sensitivity in IBS is likely to be multifactorial, and an 
involvement of postprandial visceral sensitivity and motor response, carbohydrate malabsorption, 
IgG antibodies to food, abnormal fermentation and psychological factors has been proposed 
(for review, see Simrén et al. 2007). Th e dominant mechanism is, however, suggested to be an 
exaggerated postprandial GI sensory and motor response.
Positive food skin-prick test is more oft en encountered in IBS patients compared to controls 
(Jun et al. 2006). However, specifi c foods reported to cause intolerance rarely correlate with the 
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skin-prick test results (Dainese et al. 1999) or with serum immunoglobulins (Ig) (Monsbakken et 
al. 2006). Moreover, one study shows that challenge with foods reported as symptom-provoking 
and giving positive skin-prick test results and/or serum IgG antibodies did not exacerbate GI 
symptoms, suggesting that food allergy is not involved in IBS (Zwetchkenbaum and Burakoff  
1988). An earlier study has, in contrast, confi rmed the presence of food intolerance in IBS by a 
similar food challenge trial (Jones et al. 1982). More recent studies have focused on IgG antibodies, 
which characteristically represent a more delayed response compared with IgE antibodies. Diets 
where foods giving elevated IgG titres are excluded appear to reduce GI symptom severity and 
improve rectal compliance, i.e. the ability of the gut to adapt to imposed distension (Atkinson et 
al. 2004; Zar et al. 2005). It may also be that the local, mucosal response, rather than the systemic 
response, is of greater importance in the possible food intolerance linked to IBS. Methods 
investigating the mucosal, immunologic response to antigen or food challenge have turned out 
to be promising in detecting intestinal food allergy in cases where a skin-prick test or serum IgE 
test is negative (Bischoff  et al. 1997; Lin et al. 2002). 
Among adverse reactions to foods in IBS, carbohydrate malabsorption is repeatedly suggested 
as a typical feature. Some studies indicate malabsorption of fructose and sorbitol in functional GI 
disorders as assessed by breath hydrogen tests (Rumessen and Gudmand-Høyer 1988; Fernández-
Banares et al. 1993), while other data suggest similar absorption capacity in IBS cases and 
controls (Nelis et al. 1990). It seems that even though malabsorption of fructose and/or sorbitol 
is as common in healthy individuals as in IBS patients, GI symptoms are more easily produced 
in IBS (Nelis et al. 1990; Fernández-Banares et al. 1993). Th e appearance of symptoms aft er a 
fructose-sorbitol load in subjects with IBS  does not, however, correlate with the presence of 
hypersensitivity or dysmotility (Evans et al. 1998). Th e association between lactose maldigestion 
and IBS seems to be similar to that with fructose/sorbitol: lactose maldigestion is as common in 
IBS as amongst the general population, but perceived lactose intolerance is signifi cantly higher 
in IBS (Vesa et al. 1998). 
To summarise, current data on food intolerance or allergy in IBS are inconsistent, 
and it appears that speciﬁ c intolerance is be uncommon. Instead, an enhanced 
perception of postprandial events appears to account for the exacerbation of 
symptoms following meals. 
Genetics
Aggregation of symptoms of abdominal pain or bowel disturbances has been described in relatives 
of IBS patients, and familial studies suggest that a modest genetic contribution is involved in 
IBS pathophysiology (for review, see Saito et al. 2005). Findings comparing monozygotic and 
dizygotic twin pairs are controversial as a number of studies show a genetic factor in aetiology 
(Levy et al. 2001a; Bengtson et al. 2006; Lembo et al. 2007), while others fail to demonstrate a 
heredity component (Mohammed et al. 2005). It also appears that children of parents with IBS 
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tend to use health care more frequently for GI complaints than children of parents not suff ering 
from the condition (Levy et al. 2000). 
Genotyping studies reveal that IBS, and particularly a diarrhoea-predominant bowel habit, may 
be associated with diff erent polymorphisms in the serotonin transporter gene (Kim et al. 2004; 
Pata et al. 2004; Yeo et al. 2004; Park et al. 2006c; Saito et al. 2007). Moreover, a pharmacogenetic 
study suggests that polymorphisms of the serotonin transporter gene predict the response to 5-HT3 
antagonist therapy (Camilleri et al. 2002a). Besides putative serotonin transporter polymorphisms, 
little is known about other genetic variants that may aff ect expression of irritable bowel syndrome. 
In addition to genetic inheritance, the tendency of IBS to run in families could also be due to 
social learning (Levy et al. 2000). Parental modelling and reinforcement of illness behaviour seem 
to contribute to the development of IBS with an eff ect at least as large as heredity. 
2.1.6 Current treatment of IBS
General aspects
Up-to-date treatment recommendations for irritable bowel syndrome are presented in the Rome 
III consensus document for functional bowel disorders (for review, see Longstreth et al. 2006). 
A caring and therapeutic physician-patient relationship is one of the cornerstones of treatment. 
A confi dent diagnosis, assurance of the benignity of the condition, an explanation for why 
symptoms occur and suggestions on how to cope with them are key elements. Th e patient’s need 
for reassurance and knowledge is refl ected in health care utilisation, as those patients feeling 
insuffi  ciently informed will have more health care visits (O’Sullivan et al. 2000b). Th e type and 
the severity of symptoms along with possible psychosocial features determine the management 
regimen (for review, see Longstreth et al. 2006). Overall, patients have more confi dence in the 
eff ectiveness of education and advice about lifestyle modifi cation than in pharmacotherapy 
(Whitehead et al. 2004). Th e lifestyle recommendations most frequently given by physicians 
include dietary and exercise advice.
Dietary recommendations
Regular and unhurried meals are recommended, and unnecessary restriction of the diet should 
be avoided. Exclusion of lactose is unlikely to reduce symptoms (Parker et al. 2001), whereas 
a reduced intake of fructose and sugar alcohols may be helpful (Nelis et al. 1990; Fernández-
Banares et al. 1993). Individualised dietary manipulation based on IgG antibodies cannot be 
recommended until further data are available (for review, see Longstreth et al. 2006), although there 
are promising fi gures suggesting that patients may benefi t from these exclusion diets (Atkinson 
et al. 2004; Zar et al. 2005). Increased dietary fi bre is inexpensive and safe, and a majority of 
physicians recommend higher fi bre intake as a primary treatment means in IBS patients (Mitchell 
and Drossman 1987). Th e clinical evidence for fi bre in IBS management is inconclusive, since 
placebo-controlled trials indicate that the effi  cacy of bran is no better than placebo (Lucey et al. 
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1987; Snook and Shepherd 1994; Rees et al. 2005), except for constipation (Cann et al. 1984a). 
Flatulence may even exacerbate with fi bre (Snook and Shepherd 1994). On the other hand, it 
should be remembered that fi bres diff er in their properties. Generally, soluble fi bre appear to be 
benefi cial, while symptom worsening is typically associated with insoluble fi bre (for review, see 
Bijkerk et al. 2004). Despite this, fi bre sources containing insoluble fi bre (e.g. psyllium husk) are 
also recommended in the Rome III criteria (for review, see Longstreth et al. 2006).
Pharmacological treatment
Pharmacotherapy is not necessary for all IBS patients, but when needed, it should be directed 
towards the predominant symptom (Table 4). Signifi cant methodological inadequacies were 
recognised in early IBS trials, and the classic publication by Klein (1988) almost two decades 
ago concludes that not a single study off ers convincing evidence that any therapy is eff ective in 
treating IBS. In spite of improvement in the design of more recent trials, a current meta-analysis 
sums up that many of the routinely used therapies for IBS are of dubious effi  cacy (Lesbros-
Pantofl ickova et al. 2004). Limited evidence for the effi  cacy, safety and tolerability of current 
therapies is particularly relevant for Europe, since alosetron and tegaserod, classifi ed as the best 
documented medications, are not available in Europe (for review, see Heading et al. 2006). Almost 
half of the patients taking prescribed medication consider it ineff ective (Dapoigny et al. 2004). 
Finnish guidelines for IBS management follow the Rome criteria, though novel serotonergic 
medicines are not yet available (Silvennoinen 2002; Hillilä and Färkkilä 2004a).
Diarrhoea is treated primarily with the synthetic opiate derivative loperamide on an as-
needed basis. Th ere is good evidence from placebo-controlled studies that loperamide is eff ective 
in reducing bowel frequency and loose stools, but it does not improve abdominal pain or global 
IBS symptoms (Cann et al. 1984b; Hovdenak 1987; Efskind et al. 1996). Cholestyramine is a 
second-line treatment if bile acid malabsorption is suspected to play a role in diarrhoea (Sinha 
et al. 1998). Alosetron, a selective 5-HT3 receptor antagonist, can decrease pain, urgency and 
stool frequency as well as improve global status in women with IBS-D (Camilleri et al. 2001; 
Chey et al. 2004; Lembo et al. 2004; Krause et al. 2007). Severe adverse eff ects (ischaemic colitis 
and constipation) led to its withdrawal from the market, but it was reintroduced in the US with 
its indication restricted to women with severe IBS-D. A meta-analysis concludes that alosetron 
positively infl uences global symptoms, pain and discomfort in non-constipated women, but that 
the role of alosetron in male patients is unclear (Cremonini et al. 2003).
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Table 4.  Pharmacotherapy for IBS as advised by the Rome III criteria    
 (modiﬁ ed from Longstreth et al. 2006). 
Predominant symptom Medication
Diarrhoea Loperamide
Cholestyramine resin
Alosetrona
Constipation Psyllium husk
Methylcellulose
Calcium polycarbophil
Lactulose syrup
70% sorbitol
Polyethylene glycol 3350
Tegaserodb
Abdominal pain Smooth-muscle relaxantc
Tricyclic antidepressants
Selective serotonin reuptake inhibitors
aFor severe IBS, women. Available only in the US.
bFor IBS, women. Unavailable in the European Union. 
cSelective antimuscarinic agents unavailable in the US.
Th e recommended treatment for IBS with constipation is increased dietary fi bre or commercial 
fi bre analogues. Fibre decreases the whole-gut  transit time (Cann et al. 1984a), but it does not 
improve pain or diarrhoea (Lucey et al. 1987; Snook and Shepherd 1994; Rees et al. 2005). High 
intake of fi bre may also cause increased fl atulence in some subjects, and an individual approach 
to the increase in fi bre should be applied (Snook and Shepherd 1994). A number of studies 
demonstrate the effi  cacy of the partial 5-HT4 agonist tegaserod in improving stool frequency 
and consistency as well as in reducing pain and bloating in IBS-C (Müller-Lissner et al. 2001; 
Layer et al. 2005; Tack et al. 2005). Similarly to alosetron, tegaserod was withdrawn from the 
market due to severe adverse eff ects, but later reintroduced in some markets with tightened 
indication for women only. Various smooth-muscle relaxants are frequently prescribed for 
predominant abdominal pain. A meta-analysis evaluates the available evidence for their use in 
IBS as “inconsistent results from inadequately controlled clinical trials or poor quality cohort 
studies” (Lesbros-Pantofl ickova et al. 2004). Not all smooth-muscle relaxants are eff ective in IBS, 
but some agents, including cimetropium bromide (Centonze et al. 1988; Dobrilla et al. 1990), 
octylonium bromide (Battaglia et al. 1998; Glende et al. 2002) and peppermint oil (Liu et al. 
1997; Cappello et al. 2007), appear to be eff ective, bearing in mind, however, the inadequacies 
in study designs. Serotonergic modulators, including antidepressants and selective serotonin 
reuptake inhibitors, may exert their action at both the peripheral and central level of the brain-
gut axis since they possess psychotropic properties as well as neuromodulatory and analgesic 
35
properties (for reviews, see Clouse 2003; Kilkens et al. 2003). Th e evidence for the use of tricyclic 
antidepressants in IBS is favourable (Greenbaum et al. 1987; Tanum and Malt 1996; Drossman 
et al. 2003), but due to serious side-eff ects, these medicines should only be used in subjects with 
severe abdominal pain. 
Investigational medicines
Several compounds aff ecting various sites of the brain-gut axis are currently being investigated for 
their potential to alleviate symptoms of IBS. In addition to alosetron and tegaserod, other 5-HT3 
and 5-HT4 antagonists and agonists have been evaluated. Cilansetron, a 5-HT3 antagonist, has 
shown in phase III clinical trials eff ects similar to alosetron (Chey and Cash 2005). A full 5-HT4 
agonist prucalopride accelerates transit time in healthy subjects and in patients with functional 
constipation (Bouras et al. 1999; Bouras et al. 2001). Clonidine, an α2 adrenergic agonist, relaxes 
the bowel, reduces pain sensation and has shown clinical promise in IBS-D (Camilleri et al. 
2003). Th e ĸ-opioid agonists fedotozine and asimadoline may reduce pain hypersensitivity in IBS 
(Dapoigny et al. 1995; Delgado-Aros et al. 2003). Th e neurokinin-1 and -3 receptor antagonists 
appear to play a role in disrupted motility and visceral sensitivity, and preliminary experimental 
and clinical data are promising (Lördal et al. 2001; Okano et al. 2002). One randomised, double-
blind, placebo-controlled trial indicates that pregabalin, an α2δ ligand used for neuropathic 
pain, has favourable eff ects on visceral hypersensitivity by increasing rectal sensory thresholds 
(Houghton et al. 2007b).
Psychological treatment
Psychological treatments may be useful in patients with moderate to severe symptoms when 
medical treatments have failed or when there is proof that stress or psychological factors exacerbate 
symptoms (for review, see Drossman et al. 2002). Interpersonal psychotherapy, relaxation/stress 
management and cognitive behavioural therapy are the most common approaches that have been 
considered in IBS. Critical evaluation of the effi  cacy of psychological treatments is hampered 
by the fact that trials cannot be double-blind, even though certain studies have included some 
form of control or placebo group. Generally, psychological treatment is time-consuming and 
expensive, and in many circumstances it is unavailable, which further limits its employment in 
IBS management (for review, see Longstreth et al. 2006). Hypnotherapy, one form of cognitive 
behavioural therapy, is one of the most widely studied psychological treatments in IBS. Hypnosis 
can improve GI symptoms and quality of life (Houghton et al. 1996; Gonsalkorale et al. 2002) 
as well as rectal hypersensitivity (Prior et al. 1990a; Lea et al. 2003) in IBS. However, a recent 
Cochrane review (Webb et al. 2007) identifi ed 25 studies on hypnotherapy in IBS, but included 
only four in the fi nal review aft er excluding methodologically inadequate trials. Th ough hypnosis 
was found to be superior to usual medical management in those patients who fail standard therapy, 
the low number of high-quality trials does not allow for any conclusions to be drawn.
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Taken together, the treatment of IBS demands a good and caring physician-patient 
relationship combined with reassurance and education. Individual dietary and lifestyle 
modiﬁ cations frequently alleviate the symptoms, and many patients do not need 
medical treatment. When required, pharmacotherapy should target the predominant 
symptom. Diarrhoea is treated primarily with loperamide, constipation with dietary 
ﬁ bre or commercial ﬁ bre analogues and pain with smooth-muscle relaxants and 
serotonergic agents. Overall, the efﬁ cacy of treatments is limited.
2.2 Human intestinal microbiota
With an approximated area between 250 and 400 m2, the GI tract constitutes one of the largest 
body surface areas. It is inhabited throughout by a complex microbial ecosystem, and the number 
of microbial cells in the human body is estimated to be 10 times the number of eukaryotic cells 
(for review, see Savage 1977). Based on fi ndings from cultivation-based studies, it was estimated 
that about 400 species make up the GI tract microbiota (Moore and Holdeman 1974). However, 
novel data incorporating information from genome-based approaches suggest that the microbiota 
includes over 1,200 distinct micro-organisms (for reviews, see Zoetendal et al. 2006; Rajilić-
Stojanović et al. 2007). Importantly, the description of the human microbiota diversity is an 
ongoing process, and complete coverage has not yet been achieved. 
2.2.1 Composition and functions
Th e intestinal microbiota in healthy adults is generally considered highly individual and stable 
over time (Zoetendal et al. 1998; Vanhoutte et al. 2004). Environmental factors, e.g. antimicrobials, 
dietary modifi cations, certain diseases and psychological stress can, however, alter an otherwise 
stable microbiota (for review, see Th ompson-Chagoyán et al. 2007). Th e individuality of 
microbiota is emphasised in a recent study showing that 62% of the 395 bacterial phylotypes 
identifi ed were novel when the microbiota of three subjects were characterised (Eckburg et al. 
2005). Furthermore, the inter-individual variation was far greater than variability between one 
subject’s faecal and mucosal communities. Th e great majority (97%) of the inhabitants of the GI 
tract ecosystem are strict anaerobes, while the rest are aerobes or facultative anaerobes (for review, 
see Noverr and Huff nagle 2004). A limited number of bacterial groups make up the dominant 
microbiota. Based on molecular methods, the two dominant groups, Clostridium coccoides-
Eubacterium rectale (28%) and Clostridium leptum (25%), represent more than half of the total 
bacteria (Lay et al. 2005). Within the C. leptum group, Faecalibacterium prausnitzii is the most 
commonly found cluster. Th e most abundant bacterial groups aft er C. coccoides and C. leptum 
are Bacteroides (9%), Bifi dobacterium (4%) and Atopobium (3%). Th e Lactobacillus-Enterococcus 
group represents approximately 2% of the total bacteria.
Bacterial colonisation varies strongly in diff erent parts of the GI tract. Th e oral cavity is 
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a heterogeneous environment with diff erent bacterial groups predominating in the mucous 
membranes, teeth and tongue, and with approximately 107 to 108 bacteria/g in saliva (for 
review, see Liljemark and Bloomquist 1996). Due to the acidic environment, levels below 103 
cfu/g are usually found in gastric contents (for review, see Salminen et al. 1998). Th e small 
intestinal bacterial numbers range from 104 to 107 cfu/g, with the highest levels found close to 
the ileocaecal region. Th e colon is by far the most vastly populated section, since it harbours as 
much as 1011 to 1012 bacteria/g. Th e composition of the microbiota diff ers along the length of 
the GI tract, and similarly cross-sectionally, since diff erent bacterial communities inhabit the 
lumen and the mucosa (for review, see Noverr and Huff nagle 2004). It is noteworthy that most 
of the available knowledge on intestinal microbiota composition is based on faecal samples, 
and the mucosa-associated and faecal bacterial communities appear to diff er from each other 
(Zoetendal et al. 2002; Ouwehand et al. 2004; Eckburg et al. 2005; Lepage et al. 2005). Strictly 
speaking, intestinal microbiota and faecal microbiota are thus not synonyms. In this study, 
however, the term intestinal microbiota is used as a general term for the GI tract ecosystem 
regardless of the sample material where the microbes have been detected. Th e mucosal microbiota 
is considered fairly stable in diff erent locations throughout the colon (Zoetendal et al. 2002; 
Lepage et al. 2005). 
Th e intestinal microbiota has a considerable infl uence on host health and disease, both in 
the GI tract and systemically (for review, see Guarner 2006). Metabolic, protective and trophic 
eff ects are considered the key functions of the gut microbial community (Figure 2). Much 
of the evidence of the role of microbiota in physiology derives from experiments in germ-
free animals. Th ese experiments demonstrate major diff erences in e.g. organ weights, cardiac 
output, body temperature, intestinal morphology and immunological parameters between 
conventional and germ-free animals (for review, see Tannock 2001). Th e metabolic activity 
of the microbiota results in the production of various potentially benefi cial or harmful end 
products. Carbohydrate fermentation produces short-chain fatty acids (SCFAs), which act as an 
energy source for colonocytes and regulate water and electrolyte absorption (Scheppach 1994). 
Among SCFAs, butyrate has gained most attention, and it appears to have several advantageous 
eff ects on colonic function, though a topical review calls for more clinical evidence (Hamer 
et al. 2007). Th e protective functions of the microbiota refer to the barrier eff ect, also known 
as colonisation resistance, which the commensal bacteria provide against potential pathogens 
(van der Waaij 1982). Considering trophic functions, interactions between the microbiota and 
the immune system are the subject of considerable investigation. In addition to results from 
germ-free animals, clinical data in allergic infants imply that gut bifi dobacterial composition 
plays an essential role in the maturation of the immune system (He et al. 2001; Ouwehand 
et al. 2001; Suzuki et al. 2007). Even if bifi dobacteria appear to be central for immunity, the 
physiological relevance of individual bacterial groups is generally not well-established as studies 
on germ-free animals primarily demonstrate a diff erence between the presence and absence 
of the microbiota. Further indirect evidence on the signifi cance of the microbiota for human 
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health and physiology is provided by studies showing an aberrant microbiota composition in 
certain diseases, for example, IBD (for review, see Seksik et al. 2006). 
Figure 2.  Main functions of the intestinal microbiota (modiﬁ ed from Guarner 2006).
Taken together, the characterisation of the microbiota is an ongoing process, and 
the number of micro-organisms inhabiting the GI tract is currently estimated to be 
more than 1,200. The adult microbiota is considered highly individual and rather 
stable over time. The microbiota has several essential functions affecting both the 
GI tract and systemic physiology. 
2.2.2 Overview of methods for analysing microbiota
Until recent years, cultivation-based methods were the most widely applied means of studying 
the GI microbiota (for review, see Furrie 2006). Th e advantages of plate count analysis include 
its broad availability, its relative inexpensiveness as well as its potential for quantifying bacterial 
populations. One serious limitation of plating is that its applicability is restricted to cultivable 
organisms, whereas it has been proposed that only between 30% and 40% of the GI tract microbiota 
can be cultured by currently available methods (Hayashi et al. 2002). Th e development of culture-
independent, molecular methods built on microbial nucleic acid sequence information has 
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contributed to a dramatic increase in the knowledge of intestinal microbiota diversity. 
It is well-established that the bacterial ribosomal deoxyribonucleic acid (rDNA) gene contains 
both highly conserved regions, which are identical for all bacteria, as well as variable regions that 
can be used for identifi cation of bacterial species or groups, and in some cases even strains (for 
review, see Furrie 2006). Particularly the 16S ribosomal ribonucleic acid (rRNA) gene sequence is 
commonly used to identify bacteria. Examples of methods taking advantage of this phenomenon 
are qPCR, temperature/denaturing gradient gel electrophoresis, fl uorescent in situ hybridisation 
(FISH) and DNA microarrays. Depending on the method used, the composition, genomic 
diversity or activity of the microbiota can be investigated (for review, see Zoetendal et al. 2006). 
Each method has its own advantages and disadvantages, but in relation to culturing, the main 
advantages of molecular biology are the detection of uncultivable species, no requirement for 
anaerobic handling and, with some methods, the possibility to analyse a large amount of bacterial 
targets simultaneously (for review, see Furrie 2006). Among the shortcomings are that not all of 
the methods are quantitative and that a number of techniques are still rather expensive. One fi eld 
of molecular biology where upcoming research activity is predicted is metagenomics, analysis 
of the collective genome or “microbiome” of a defi ned microbial population. As for intestinal 
microbiota, metagenomics has provided estimates that the combined number of micro-organisms 
in the GI tract totals up to 1013 to 1014 (Gill et al. 2006).  
2.2.3 Intestinal microbiota in IBS
Microbiota composition 
Th e microbiota of IBS patients has been compared to that of healthy subjects both directly, by 
using conventional culturing methods or DNA-based methods, and indirectly, by measuring 
microbiota-derived metabolites. An early study applying culturing methods demonstrates 
signifi cantly lower numbers of coliforms, lactobacilli and bifi dobacteria in IBS patients (Balsari 
et al. 1982). Another study strengthens fi ndings on reduced counts of Bifi dobacterium spp. and 
additionally shows an increase in Enterobacteriacea (Si et al. 2004). In contrast to Balsari et al. 
(1982) a recent study, similarly using plating methods, found a signifi cantly higher number of 
coliforms in IBS (Mättö et al. 2005). No diff erences in the mean cultivable numbers of bacteroides, 
bifi dobacteria, spore-forming bacteria, lactobacilli, enterococci or yeasts were found, but an 
increased aerobe:anaerobe ratio could be seen. 
Amongst culture-independent methods, FISH analysis indicates a higher total bacterial 
population in IBS patients vs. healthy subjects (Swidsinski et al. 2005). Th e percent-guanine-
plus-cytosine method has revealed community-level diff erences between healthy controls and 
IBS patients subtyped according to bowel habit (Kassinen et al. 2007). Subsequent identifi cation 
of the alterations showed that patients and controls diff ered particularly in Collinsella aerofaciens, 
Clostridium cocleatum -related and Coprococcus eutactus -related phylotype assays. A microarray-
based analysis with the Human Intestinal Tract Chip (HITChip) has revealed that the total microbiota 
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of IBS patients is more heterogeneous than that of healthy controls (Rajilić-Stojanović 2007). Th e 
microbiota in IBS is also characterised particularly by lower levels of Bacteroides and increased 
levels of the bacilli order. Th e diff erent IBS subtypes appear to diff er with regard to microbiota. 
Moreover, the predominant bacterial populations in IBS patients show more temporal instability 
compared to healthy controls (Mättö et al. 2005; Maukonen et al. 2006) as well as more changes 
in the clostridial population (Maukonen et al. 2006). An abnormal pattern of faecal short-chain 
fatty acids (Treem et al. 1996), characterised by lower levels of total SCFA, acetate and propionate, 
and higher levels of n-butyrate, also points towards an imbalanced microbiota in IBS.
Small intestinal bacterial overgrowth 
Th e possibility that small intestinal bacterial overgrowth could explain the occurrence of IBS 
symptoms, particularly bloating, is supported by abnormal lactulose breath tests in IBS as well 
as by an improvement of GI symptoms aft er eradication of the overgrowth. According to some 
studies, 30 to 80% of IBS patients may have small intestinal bacterial overgrowth as diagnosed 
by lactulose breath test (Pimentel et al. 2000; Pimentel et al. 2003a) or glucose breath test 
(Lupascu et al. 2005). However, not all studies support bacterial overgrowth in IBS (Walters and 
Vanner 2005). Based on whole-body calorimeter analysis, lactulose ingestion causes increased 
gas excretion in IBS patients (King et al. 1998). Randomised, double-blind, placebo-controlled 
studies show an improvement in GI symptoms and a normalisation of the lactulose breath test 
aft er eradication of overgrowth by antimicrobials (Pimentel et al. 2003a; Pimentel et al. 2006a). 
In addition to elevated hydrogen following a lactulose load, methane production has also been 
associated with IBS, mainly with the constipation-predominant subtype (Pimentel et al. 2003b; 
Chatterjee et al. 2007). Th is is consistent with fi ndings showing that methane is able to slow gut 
transit time (Pimentel et al. 2006b). 
To summarise, no single deviance has been identiﬁ ed in IBS microbiota, but various 
quantitative and qualitative alterations in the gut bacterial composition have, 
nonetheless, been indicated by a range of techniques. Consequently, an increasing 
amount of evidence supports the hypothesis of microbiota involvement in IBS 
pathophysiology. 
2.2.4 The association between microbiota alterations and gut 
dysfunction
Th ough the microbiota appears to play a part in IBS, it is unclear whether alterations in the 
microbiota are a cause of IBS or a result of e.g. disturbed gut motility induced by the syndrome. 
Commensal bacteria are central to the development and maintenance of normal gut sensory and 
motor functions, as is shown by studies in germ-free animals (Husebye et al. 2001). An altered 
microbiota may disrupt this cross-talk between bacteria and the epithelium, and as a result 
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contribute to sensory-motor dysfunction in IBS (for review, see Barbara et al. 2005). Infl ammation 
induced by bacteria is another mechanistic framework for how commensal microbes may 
induce IBS symptoms. Studies on IBD imply that the microbiota is able to trigger and perpetuate 
mucosal infl ammation (Linskens et al. 2001). Experimental models subsequently demonstrate 
that a causal relationship exists between mucosal infl ammation, altered GI motor function and 
visceral hypersensitivity (for review, see Collins 1996). Bacterial lipopolysaccharide is another 
putative agent involved in the development of visceral hypersensitivity (Coelho et al. 2000). 
Metabolites produced by the intestinal microbiota may also be active participants in symptom 
generation since SCFAs have been suggested as playing a part in gut motor functions (Husebye 
et al. 2001; Fukumoto et al. 2003).
2.3 Probiotics 
2.3.1 Deﬁ nition and health effects
An expert group appointed by the World Health Organization and the Food and Agricultural 
Organization of the United Nations defi ned probiotics as ‘live microorganisms which when 
administered in adequate amounts, confer a health benefi t on the host’ (WHO 2001). According 
to this report, potential probiotic micro-organisms should possess certain fundamental 
properties: they should survive through the GI tract, be capable to proliferate in the gut, and 
be safe for use. Th e most frequently used probiotics are lactobacilli or bifi dobacteria, but other 
micro-organisms from the genera Propionibacterium, Bacillus, Escherichia, Enterococcus and 
Saccharomyces are also being increasingly used and assessed for future use. Studies investigating 
the properties of probiotics have revealed that each bacterial strain is unique, and that health 
eff ects are consequently strain-specifi c (for review, see Saxelin et al. 2005). As for clinical health 
eff ects, probiotics are, nonetheless, oft en viewed upon as a group. In the above analyses, the relief 
of lactose intolerance symptoms, the prevention and treatment of acute diarrhoea in children 
and the reduction of the risk of antibiotic-associated diarrhoea are generally considered to be 
the best-documented eff ects (for reviews, see Ouwehand et al. 2002a; Saxelin et al. 2005; Doron 
and Gorbach 2006). Interesting fi elds include the relief of atopic diseases in children and the 
reduction of the risk of atopic diseases, where particularly Lactobacillus rhamnosus GG (LGG) 
has demonstrated promising results (Majamaa and Isolauri 1997; Isolauri et al. 2000; Viljanen 
et al. 2005b; Kalliomäki et al. 2007). 
Th e mechanisms by which probiotics exert their health eff ects are not fully understood, 
but the promotion of the host defence systems, modulation of the immune system as well as 
the competitive exclusion of harmful microbes are thought to be key elements (for review, see 
Saxelin et al. 2005). However, strains diff er in their characteristics and it is therefore likely that 
selected mechanisms are also strain-specifi c. Th e awareness of the strain-specifi city of probiotics 
has paved the way for the idea to combine specifi c probiotic strains in order to obtain additive 
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eff ects. A multispecies probiotic is defi ned as ‘containing strains of diff erent probiotic species 
that belong to one or preferentially more genera’ (for review, see Timmerman et al. 2004). It has 
been suggested that multispecies probiotics may in some conditions be more effi  cient than single 
strains due to their synergistic or additive eff ects as refl ected in e.g. enhanced intestinal adhesion, 
the production of a greater variety of antimicrobial compounds and the ability to colonise 
several niches of the GI tract. As an example, certain species of Bifi dobacterium, Lactobacillus 
and Streptococcus have been shown to display diff erent eff ects on gut motility (Massi et al. 2006), 
indicating that a combination of diff erent species could give a more versatile eff ect on motility 
disturbances. Moreover, each strain in a multispecies probiotic comprising LGG, L. rhamnosus 
Lc705 (Lc705), Propionibacterium freudenreichii subsp. shermanii JS (PJS) and Bifi dobacterium 
breve Bb99 (Bb99) or B. animalis subsp. lactis Bb12 (Bb12) is adherent to mucus in vitro (for 
review, see Collado et al. 2006), but the presence of LGG more than doubles the adhesion of Bb12 
and certain Propionibacterium strains (Ouwehand et al. 2000; Ouwehand et al. 2002b). 
A European expert group concludes in its review that the ingestion of lactobacilli and 
bifi dobacteria is considered to be safe in both healthy and immunosuppressed individuals 
(Borriello et al. 2003). Infections caused by these bacteria are exceptionally rare, and identifi ed 
cases have been isolated in severely ill patients (Presterl et al. 2001; De Groote et al. 2005; Ledoux 
et al. 2006). Importantly, data from Finland show that a signifi cant growth in the consumption of 
LGG at the population level has not led to an increase in the number of Lactobacillus bacteraemias 
(Salminen et al. 2002). Th ough particularly lactobacilli and bifi dobacteria are regarded as safe, 
a safety evaluation based on the origin of the strain and on the presence of intrinsic antibiotic-
resistance genes should be undertaken when the introduction of new probiotic strains is being 
considered (for review, see Borriello et al. 2003). However, it should be kept in mind that it is 
not always possible to determine the origin of a strain.
2.3.2 Clinical trials on probiotics in IBS
A number of randomised, placebo-controlled trials on the effi  cacy of probiotics or combinations 
of probiotics in IBS have been published (Table 5). One trial using a combination of lactobacilli 
and bifi dobacteria or placebo concluded that no statistical analyses could be conducted due to 
the small sample size, and was therefore excluded from Table 5 (Saggioro 2004). Furthermore, a 
few uncontrolled trials with various designs have been published (Brigidi et al. 2001; Bazzocchi 
et al. 2002; Drisko et al. 2006; Fan et al. 2006), but due to the extremely high placebo response 
associated with IBS (Patel et al. 2005), no conclusions can be drawn form these studies. Overall, 
trials are highly heterogeneous concerning symptom questionnaires and outcome measures, which 
makes it complicated to compare the effi  cacy of diff erent strains. B. infantis 35624 (O’Mahony 
et al. 2005; Whorwell et al. 2006) and VSL#3 (Kim et al. 2003; Kim et al. 2005b), a probiotic 
combination comprising eight diff erent strains, are the only formulations that have demonstrated 
a consistent and benefi cial eff ect in two trials. L. plantarum 299v has alleviated IBS symptoms in 
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two studies (Nobaek et al. 2000; Niedzielin et al. 2001), whereas a third one failed to see any eff ect 
(Sen et al. 2002), possibly due to a lower administration dose. Similar to IBS trials in general, 
studies on probiotics suff er from methodological inadequacies, including the use of relatively 
small sample sizes and the lack of long-term data. 
To summarise, the current evidence suggests a role for probiotics in the management 
of IBS, but further trials are needed before general guidelines for speciﬁ c probiotics 
can be designed. The great majority of trials suffer from methodological shortages, 
and almost no long-term data are available.
2.3.3 Mechanisms of action of probiotics in IBS
Diverse types of mechanisms appear to account for the reduction by probiotics of IBS symptoms. 
Th ese include eff ects mediated via modulation of the microbiota, the immune system, gut motility 
and visceral hypersensitivity or pain sensing. 
Th e microbiota and its metabolites, primarily SCFAs, aff ect the maturation and maintenance of 
gut sensory and motor functions as well as the gut barrier function (van der Waaij 1982; Husebye 
et al. 2001; Fukumoto et al. 2003). Probiotic supplementation can infl uence the composition 
and metabolism of the microbiota (Siigur et al. 1996; Kuisma et al. 2003) and decrease intestinal 
permeability (Isolauri et al. 1993; Lam et al. 2007) and consequently modulate gut function. 
Observations on microbiota alterations by probiotics are, however, general fi ndings, and the 
phenomenon has not been demonstrated specifi cally in IBS. Only one controlled trial on IBS 
and probiotics has monitored possible alterations in microbiota during L. plantarum 299v 
supplementation, but it only found an increase in Enterococcus in the placebo group (Nobaek et 
al. 2000). Uncontrolled studies have reported VSL#3 as increasing faecal ß-galactosidase activity 
and decreasing urease activity (Brigidi et al. 2001; Bazzocchi et al. 2002). Infl ammation and 
altered immune response is recognised as one feature of IBS (Dunlop et al. 2003b; O’Mahony et 
al. 2005; Barbara et al. 2007; Liebregts et al. 2007b). Certain probiotics possess anti-infl ammatory 
and immunomodulatory eff ects (Schultz et al. 2003), which could explain their benefi cial role in 
gut dysfunction. Th e credibility of immunomodulation in relation to other putative mechanisms 
is increased by the fact that this is the only mechanism that has been shown to correlate with 
clinical symptom reduction in a human trial on IBS (O’Mahony et al. 2005). 
In vitro studies on isolated intestines of guinea pigs have shown that probiotics, especially 
bifi dobacteria, have a relaxing eff ect on the colon (Massi et al. 2006). L. paracasei NCC2461 also 
appears to attenuate muscle hypercontractility in a mouse model of post-infectious IBS as evaluated 
by gut contractility measures (Verdu et al. 2004) and a high-throughput metabolomic approach 
(Martin et al. 2006). A recent experimental study with a combination of two Lactobacillus strains 
saw a normalisation of stress-induced gut dysfunction, possibly due to normalisation of the 
hypothalamus-pituitary-adrenal axis (Gareau et al. 2007). Experimental fi ndings are corroborated 
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by clinical studies on VSL#3 in IBS, demonstrating that the probiotic reduces colonic motor 
responses to balloon distension in an uncontrolled setting (Bazzocchi et al. 2002) and retards 
colonic transit time vs. placebo (Kim et al. 2005a). As for probiotics and pain, a study in rats 
proves that L. reuteri (ATCC 23272) can inhibit visceral pain through eff ects on enteric nerves 
(Kamiya et al. 2006). Similarly, experimental hypersensitivity induced by antibiotics or stress 
may be suppressed by L. paracasei NCC2461 and L. farciminis (Ait-Belgnaoui et al. 2006; Verdu 
et al. 2006; Eutamene et al. 2007). It has been suggested that stress-induced hypersensitivity is 
caused by an increase in permeability (Ait-Belgnaoui et al. 2005) that, equally to  hypersensitivity, 
can be counteracted by selected probiotics (Zareie et al. 2006; Eutamene et al. 2007). On the 
molecular level, it has been shown that certain Lactobacillus strains can induce the expression of 
pain-suppressing μ-opioid and cannabinoid receptors in intestinal epithelial cells (Rousseaux et 
al. 2007). Th e mechanism underlying this discovery remains unknown, but direct contact of the 
lactobacilli with the epithelium results in the induction of these receptors via the nuclear factor-
κB pathway. Th e applicability of mechanistic data is impaired by the fact that the great majority 
of strains that have been investigated in mechanistic studies have no clinical substantiation for 
their effi  cacy.
To summarise, probiotics are likely to exert their favourable effects on gut dysfunction 
and discomfort via several mechanisms. Some mechanisms of action may be 
speciﬁ c to certain bacterial strains or species, whereas other mechanisms may be 
a general feature of probiotic bacteria. However, more clinical data on mechanisms 
is needed. 
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3. AIMS OF THE STUDY
Th e exact aetiology and pathophysiology of IBS remain unidentifi ed, even though elements such 
as visceral hyperalgesia, altered motility and disturbed brain-gut communication appear to be 
central. Current treatments for IBS are considered rather unsatisfactory. Previous data indicate 
that certain probiotic strains or combinations of strains may be benefi cial in IBS. However, the 
mechanism of action behind clinically effi  cient probiotics is not well known. Th e aim of the present 
study was to investigate the pathophysiology of IBS and the role of probiotic supplementation 
in the treatment of the syndrome.
The specific aims of the study were:
Pathophysiology ? : To investigate pathophysiological factors of IBS by comparing the 
intestinal microbiota composition and the mucosal metabolic profi le of IBS patients with 
the corresponding variables in healthy control subjects (Studies I, V).
Probiotic supplementation ? : To clarify the eff ects of long-term multispecies probiotic 
supplementation on gastrointestinal symptoms and quality of life in IBS (Studies II, 
IV).
Characterisation of probiotic action ? : To fi nd out the eff ects of the probiotic supplementation 
on intestinal microbiota composition, metabolism and stability, and on systemic 
infl ammatory markers (Studies III, IV).
48
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4. MATERIALS AND METHODS
Th e description of the study design, duration and outcome measures, as well as the demographic 
characteristics of the subjects are presented in Table 6. Th e subjects comprised adult IBS patients 
(I-V) and healthy control subjects (I, V). 
4.1 Subjects
IBS patients were recruited from primary care units (Helsinki and Tampere, Finland) by 
experienced endoscopists. Most subjects fulfi lled the Rome II criteria for IBS, while the rest 
fulfi lled the Rome I criteria (Table 2). IBS patients were predominantly female. Healthy subjects 
devoid of GI diseases or symptoms were recruited as controls. 
4.1.1 IBS patients 
Th e inclusion criteria for IBS patients were: an IBS diagnosis consistent with the Rome I or II criteria 
for IBS (Th ompson et al. 1992; Th ompson et al. 1999), an age between 20 and 65 years, a clinical 
investigation with endoscopy or barium enema of the GI tract performed within one year (I-III) 
or fi ve years (IV, V) prior to the study, and a normal blood count and serum creatinine, alanine 
aminotransferase and alkaline phosphatase values within reference limits (IV, V). Patients who 
were pregnant or lactating, had organic intestinal diseases or severe systemic diseases, previous 
major or complicated abdominal surgery, severe endometriosis or complicated abdominal 
adhesions, received antimicrobials during the preceding one to two months, had dementia or 
were otherwise unable to co-operate adequately were excluded. Subjects participating in Study 
V additionally had normal gut histology as evaluated by an experienced pathologist. IBS patients 
in Studies I and III were subgroups of the patients participating in Study II.
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4.1.2 Healthy control subjects 
Controls subjects in Study I were recruited by advertisements at the Technical Research Centre 
of Finland, whereas subjects undergoing colonoscopy for clinical reasons were recruited via 
endoscopists into Study V. Th e inclusion criteria for the controls subjects were: overall healthiness 
and an age between 20 and 65 years. Additionally, subjects in Study V had normal blood count 
and serum creatinine, alanine aminotransferase and alkaline phosphatase values within reference 
limits as well as normal gut histology as evaluated by an experienced pathologist. 
4.2 Study designs 
Interventions were carried out in a randomised, double-blind, placebo-controlled manner with 
two parallel groups. Patients with ongoing IBS medication (e.g. fi bre analogues, antispasmodics, 
antidiarrhoeals, laxatives) or any other regular medication were allowed to continue the medication 
throughout the study. Any changes in medication, in health status or in dietary habits as well 
as antimicrobials and adverse events were recorded. All the subjects were asked to abstain from 
commercial products containing probiotics during the entire study period.
Intestinal microbiota in IBS patients and healthy controls (Study I)
Twenty-seven IBS patients and 22 healthy subjects participated in this study. During the six-month 
study period, three faecal samples were collected from all study subjects (0, 3 and 6 months) for 
the determination of intestinal microbiota composition.
Effect of probiotic supplementation on symptoms and quality of life in IBS 
patients (Study II)
One hundred and three IBS patients recruited by physicians in primary health care units 
participated in this intervention. Altogether 86 patients completed the study. Th e study consisted 
of a one-week baseline period and a six-month intervention period (Figure 3). Th e subjects were 
randomised into the probiotic (n=52) or the placebo (n=51) group according to a computer-
generated, blocked randomisation list. During the six-month intervention period, subjects received 
either probiotic or placebo supplementation daily. GI symptoms and bowel habits were followed 
using a symptom diary, which the patients fi lled in once at baseline and then for a period of one 
week each month throughout the intervention. HRQOL and dietary habits were followed by 
questionnaires at baseline, and at 3 and 6 months. 
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Figure 3. Study design in Study II.
Effect of probiotic supplementation on intestinal microbiota in IBS patients 
(Study III)
Fift y-fi ve IBS patients participated in this study. During a six-month intervention period, the 
subjects received either probiotic (n=28) or placebo (n=27) supplementation daily. Faecal samples 
were obtained in three time points: once at baseline and twice during the intervention (3 and 6 
months). Th e composition of intestinal microbiota, the concentration of SCFAs and the activity 
of bacterial enzymes were determined from faecal samples.
Effect of probiotic supplementation on symptoms, quality of life, microbiota 
stability and inflammatory markers in IBS patients (Study IV)
Eighty-six IBS patients recruited by a physician in primary health care participated in this 
intervention. Altogether 71 patients completed the study. Th e study consisted of a three-week 
washout period, a fi ve-month intervention period and a three-week follow-up period (Figure 4). 
Th e subjects were randomised into the probiotic (n=43) or the placebo (n=43) group according 
to a computer-generated, blocked randomisation list. During the fi ve-month intervention period 
subjects received either probiotic or placebo supplementation daily. GI symptoms and bowel 
habits were followed by a symptom diary, which the patients fi lled in once at baseline, seven 
times during the intervention period (every 3 weeks), and once during the follow-up. HRQOL 
was recorded, and blood samples and faecal samples were collected at baseline, halfway through 
and at the end of the study. Serum sensitive C-reactive protein (CRP) and selected cytokines 
were measured from serum samples, and the intestinal microbiota stability was assessed from 
part of the patients (n=20).
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Figure 4. Study design in Study IV.
Mucosal metabolites in IBS patients and healthy controls (Study V)
Fift een IBS patients and nine healthy volunteers recruited by physicians in primary health care 
participated in this study. Mucosal biopsies from the ascending colon were obtained from each 
subject during colonoscopy in one time point. Th e global lipid- and water-soluble metabolic 
profi les of mucosal samples were determined.
4.3 Administration and doses of probiotics 
Th e intervention studies (II, IV) investigated multispecies probiotic supplementation consisting 
of four bacterial strains. Probiotic supplementation was given either as a capsule (II) or in a milk-
based drink (IV) in a randomised, double-blind, placebo-controlled manner. Th e supplementation 
comprised Lactobacillus rhamnosus GG (ATCC 53103), Lactobacillus rhamnosus Lc705 (DSM 
7061), Propionibacterium freudenreichii subsp. shermanii JS (DSM 7067), and Bifi dobacterium 
breve Bb99 (DSM 13692) in Study II or Bifi dobacterium animalis subsp. lactis Bb12 (DSM 15954) 
in Study IV. Th e probiotic capsules and drinks as well as the corresponding placebos were provided 
by Valio Ltd, Helsinki, Finland.
Th e capsules used in Study II contained 2-2.25 x 109 cfu of each strain, equalling a total 
bacterial amount of 8-9 x 109 cfu/capsule. Th e daily dose was one capsule. Study compliance was 
assessed by counting the number of capsules remaining in each carton returned by the participants 
to the study coordinator. Th e milk-based drink consumed in Study IV contained on average 1 
x 107 cfu/ml of each bacterial strain. Th e daily intake of the drink was 120 ml, equalling a total 
bacterial amount of 4.8 x 109 cfu/day. Th e drink was made up of 80% lactose-free milk and 20% 
fruit juice. Th e placebo drink was devoid of probiotics, but otherwise identical to the probiotic 
drink. Study compliance was followed by daily questionnaires.
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4.4. Questionnaires
IBS symptoms and bowel habits (Studies II and IV)
Patients participating in the intervention studies recorded throughout the study the intensity of GI 
symptoms as well as bowel habits (frequency and form of stools) in a structured symptom diary. 
Baseline symptoms were recorded for one week prior to the beginning of the intervention. Th e 
primary IBS symptoms recorded were abdominal pain, distension, fl atulence and rumbling, and 
their combined sum made up the total IBS score. Th e intensity of each symptom was measured 
on a scale of 0-4, where 0 represented absence of symptoms and 4 severe symptoms. 
Dietary habits (Study II)
Th e frequency of use of the major foodstuff s (dairy products, cereals, meat, fruit and vegetables, 
fats, and beverages) and the consumption of foods generally considered to be symptom-
provoking were assessed by a food-frequency questionnaire. Th e aim of the questionnaire was 
to obtain a general picture of the patients’ diets, and to detect possible changes in diets during 
the intervention. 
Health-related quality of life (Studies II and IV)
Th e RAND 36-Item Health Survey (Hays et al. 1993), which measures general HRQOL, was 
employed in Study II. Th e survey assesses eight health concepts: physical functioning, bodily pain, 
role limitations due to physical health problems, role limitations due to personal or emotional 
problems, general mental health, social functioning, energy/fatigue, and general health perceptions. 
Th e Irritable Bowel Syndrome Questionnaire (IBSQ) developed by Wong et al. (1998) was used in 
Study IV. Th e questionnaire assesses four domains of HRQOL: bowel symptoms, fatigue, activity 
limitations and emotional function.
4.5 Collection of samples
Faecal samples (Studies I, II, IV)
Faecal samples were collected from IBS patients in Studies II and IV, and from healthy control 
subjects in Study I. Samples obtained from IBS patients during Study II were analysed in Studies 
I and III. During Study II, three faecal samples (0, 3 and 6 months) were collected from the IBS 
patients. Samples were immediately stored in anaerobic containers from defecation onwards, 
frozen within four hours to -70 ºC, and stored therein until analysed. Samples from healthy 
control subjects in Study I were collected at the same time points and according to the same 
protocol. During Study IV, three faecal samples (baseline, mid-point, and end-of-study) were 
collected. Samples were immediately frozen at -20 ˚C, and transferred shortly into -45 ˚C for 
storage until required for analysis. 
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Blood samples (Study IV)
Blood samples were drawn at three time points: baseline, mid-point, and end-of-study (Figure 
4). Samples were immediately frozen at -20 ˚C as serum, and transferred shortly into-45 ˚C for 
storage until required for analysis. 
 
Mucosal biopsies (Study V)
Mucosal biopsies from the ascending colon were obtained from IBS patients and healthy controls 
during colonoscopy aft er bowel cleansing. Th e samples were immediately frozen at -20 °C, and 
transferred shortly into -70 °C until required for analysis.
4.6 Microbiological and biochemical determinations
4.6.1 Intestinal microbiota and its metabolism 
The composition of the intestinal microbiota (Studies I, III)
Th e composition of the microbiota was determined by real-time qPCR. A total of 21 qPCR assays 
covering more than 300 diff erent species (Table 7) were selected based on previous indications 
of an association between IBS and the bacteria in question, or due to the predominant nature 
of the group in the gut ecosystem. Total DNA was isolated from the faecal samples as described 
earlier (Apajalahti et al. 1998), and qPCR assays were performed in triplicate with an iCycler iQ 
apparatus (Bio-Rad, Hercules, CA, USA). Additionally, strain-specifi c real-time PCR assays were 
developed in Study III for the quantifi cation of each probiotic strain by using the LightCycler 
fl uorescence resonance energy transfer technique (Halme et al. 2002; Mikkola et al. 2006). 
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The stability of the intestinal microbiota (Study IV)
Th e stability of the microbiota of a subgroup of patients (n=20) was analysed in three time points 
with a microarray method, the HITChip. Th e HITChip is a custom-made Agilent microarray 
(Agilent Technologies, Palo Alto, CA, USA) designed to cover the diversity of the human 
intestinal microbiota. Th e chip contains approximately 5,500 oligonucleotide probes that cover 
all the currently known approximately 1,000 intestinal microbial species. A detailed description 
of the HITChip and the precise experimental conditions has been published separately (Rajilić-
Stojanović 2007). Th e scanning of the microarrays was performed with the Agilent Microarray 
Scanner (Agilent Technologies). Th e stability of the microbiota was assessed by the similarity 
index, obtained by constructing scatter plots of the signals for all the HITChip probes for each 
patient in each time point. Th e similarity between the time points for each individual patient 
was quantifi ed by calculating the Pearson correlation index. Th e resulting value, expressed as 
a percentage, indicates the degree of preservation of the microbiota composition between the 
time points. 
Table 7. Bacterial groups and species analysed by qPCR in Studies I and III.
Bacterial group or species
Atopobium group
Bacteroides-Prevotella-Porphyromonas
Bacteroides fragilis
Biﬁ dobacterium spp.
Campylobacter spp.
Clostridium coccoides-Eubacterium rectale
Clostridium difﬁ cile
Clostridium perfringens group
Desulfovibrio desulfuricans group
Enterococcus spp.
Escherichia coli subgroup
Faecalibacterium prausnitzii
Helicobacter-Flexispira-Wollinella
Lactobacillus group
Ruminococcus productus-Clostridium coccoides
Veillonella spp.
B. adolescentisa
B. biﬁ duma
B. catenulatum groupa
B. longum groupa
Fusobacterium spp.b
aOnly in Study I; bOnly in Study III
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Microbiota-derived metabolites (Study III)
Faecal SCFAs and bacterial enzymes were analysed at baseline, and at three and six months. Th e 
faecal SCFA content (acetate, butyrate, propionate, valerate, caproate, isobutyrate, isovalerate, 
isocaproate) and bacterial enzymes (ß-glucosidase, ß-glucuronidase) were identifi ed, as previously 
described, with gas chromatography and spectrophotometer, respectively (Goldin et al. 1980; 
Høverstad et al. 1984). 
4.6.2 Serum inﬂ ammatory markers 
In Study IV, serum sensitive-CRP and selected cytokines were measured at baseline and halfway 
through the intervention. CRP was measured by a particle-enhanced immunoturbidimetric assay 
(Roche Diagnostics, Mannheim, Germany).Th e serum cytokines interferon-γ, tumour necrosis 
factor-α and IL-2, 4, 6 and 10 were analysed with the BD Cytometric Bead Array Th 1/Th 2 kit (BD 
Biosciences, San Diego, CA, USA).
4.6.3 Mucosal metabolic proﬁ le
In Study V, a high-throughput metabolomic approach comprising lipidomics and metabolomics 
was used in order to investigate diff erences between colonic mucosa from IBS patients vs. 
healthy controls. Characterisation of lipid molecular species was performed with a lipidomics 
strategy using ultra performance liquid chromatography coupled to mass spectrometry (UPLC/
MS). Additionally, a broad screening of metabolites was conducted by comprehensive two-
dimensional gas chromatography coupled to high-resolution time-of-fl ight mass spectrometry 
(GCxGC-TOF). 
4.7. Statistical analysis
In Study I, the results are shown as means with 95% confi dence intervals (CIs) or as medians with 
interquartile ranges. Comparison between diff erent IBS subgroups as well as between IBS patients 
and healthy controls were performed by the Kruskal-Wallis test and the Mann-Whitney test. 
In Studies II and III, the main results are presented as means with 95% CIs or with the standard 
error of mean. Analysis of covariance with baseline as covariate was used for comparisons between 
the probiotic group and the placebo group concerning the main endpoints, IBS symptoms and 
microbiota. 
In Study IV, observations are presented as means, geometric means or medians with 95% CIs, 
standard deviations (SDs) or interquartile ranges. Analysis of covariance with baseline as covariate 
was used for comparison between groups in IBS symptoms and CRP, the Hodges-Lehmann 
estimate for median change was used for the HRQOL data, and the microbiota similarity index 
comparison was performed with a permutation test with exact p values. 
In Study V, partial least squares discriminant analysis (PLS/DA) was used to compare the 
metabolic profi les between IBS patients and healthy controls. Statistical comparison was made 
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using the Mann-Whitney test. 
Besides the analyses undertaken in the original articles I-V, additional statistical tests were 
undertaken for this thesis. Th e 95% CIs for microbiological data ratios (Studies I and III) and 
RAND-36 scores (Study II) were obtained by bias-corrected bootstrapping. Statistical comparison 
between patients with IBS and the age- and gender-matched Finnish population values was 
conducted by using Monte Carlo-type simulations. A meta-analysis was used to investigate the 
change in symptom score in a combination of Studies II and IV. Th e pooled mean eff ect size (d) 
estimate was calculated using direct weights defi ned as the inverse of the variance of d for each 
study. An approximate confi dence interval for d is given with a chi-square statistic and with the 
probability of this pooled eff ect size being equal to zero. 
P values below 0.05 were considered statistically signifi cant. Th e Graph Pad Prism version 3.02 
(GraphPad, San Diego, CA, USA), SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) and STATA 
version 9.0 (StataCorp, College Station, TX, USA) were used for the statistical analyses.
4.8 Ethics
Th e Human Ethics Committee of the Joint Authority for the Hospital District of Helsinki and 
Uusimaa, Finland approved the study protocol for the IBS patients in Studies I-III. Th e study 
protocol for the healthy subjects in Study I was approved by the Ethics Committee of the 
Technical Research Centre of Finland. Th e Human Ethics Committee of the Hospital District 
of Pirkanmaa, Finland approved the study protocol for Studies IV and V. All subjects gave their 
written informed consent.
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5. RESULTS
5.1 Pathophysiological factors 
Intestinal microbiota in IBS patients and healthy controls (Study I)
An extensive individual variation prevailed in the microbiota composition both among the IBS 
patients and among the control subjects. When all IBS patients were compared with healthy 
controls, quantitative alterations between patient and control groups were seen for two PCR 
assays. Based on mean bacterial numbers in the three analysed time points, lower counts for 
the C. coccoides group (10.84 log10 vs. 11.25 log10; p=0.003) and the B. catenulatum group (7.26 
log10 vs. 7.91 log10; p=0.039) were seen in IBS patients vs. healthy controls (Figure 5). When the 
diff erent subgroups of patients were compared, lower counts for Lactobacillus spp. was seen in 
diarrhoea vs. constipation (6.98 log10 vs. 7.60 log10; p=0.019), and higher counts for Veillonella 
spp. in constipation IBS compared to the healthy controls (8.30 log10 vs. 7.87 log10; p=0.045). 
Results indicate no alterations in intestinal pathogens in faecal samples of IBS patients, since C. 
jejuni was detected in one patient only, whereas Helicobacter spp. or C. diffi  cile was not detected 
in any subjects. 
Figure 5. Ratios between IBS patients (n=21) and control subjects (n=15) for analysed bacterial 
groups (log10 mean with 95% CI of 0, 3, and 6 month sample). 
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Mucosal metabolites in IBS patients and healthy controls (Study V)
In UPLC/MS, a total of 651 lipid peaks were found, and 75 of those were identifi ed. Th e most 
signifi cant upregulation among lipids was seen in proinfl ammatory cell-membrane metabolites 
lysophosphatidylcholines (p<0.001). Other lipid groups signifi cantly upregulated in IBS patients 
included lipotoxic ceramides, glyco-sphingolipids and di- and tri-acylglycerols. One hundred 
and seven mucosal metabolites were identifi ed by GCxGC-TOF. Th e metabolite contributing 
most to separation between cases and controls was 2(3H)-furanone, a cyclic ester commonly 
produced in biochemical pathways, which was almost 14-fold upregulated in IBS patients 
compared to healthy subjects (p=0.03). Furthermore, elevated levels of creatinine (p=0.004), a 
molecule involved in smooth-muscle energy metabolism, and reduced concentrations of certain 
organic carboxylic acids were observed in IBS. A PLS/DA plot combining the lipidomic and 
metabolomic data appears in Figure 6.
Figure 6. PLS/DA plot on combined lipidomic and metabolomic data in IBS patients (n=15) and 
healthy controls (n=9). LV = latent variable.
LV2
LV1
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5.2. The effect of probiotic supplementation in IBS
The effect of probiotics on GI symptoms and bowel habits (Studies II, IV)
Multispecies probiotic supplementation alleviated the symptoms of IBS. At the end of Study II, 
the treatment diff erence in the baseline-adjusted total IBS score was -7.7 points (95% CI: -13.9 
to -1.6) when the probiotic group was compared to the placebo group (p=0.015). In Study IV, 
the total IBS score had at the end of the supplementation decreased 14 points (95% CI: -19 to -9) 
in the probiotic group compared to 3 points (95% CI: -8 to 1) in the placebo group (p=0.0083). 
Results correspond to an average score reduction of 40% for the probiotic supplementation, and 
less than 10% for the placebo supplementation. Concerning individual symptoms, rumbling 
(p=0.008; Study II) and distension (p=0.023; Study IV) were most markedly alleviated. Th e 
probiotic intervention showed no eff ect on defecation frequency or stool consistency.
When combining Studies II and IV, the pooled eff ect size was -0.38 (95%CI: -0.68 to -0.09; 
p=0.012; Figure 7). 
Figure 7. Effect size meta-analysis plot for change in IBS symptom score in Studies II (n=91) 
and IV (n=86).
The effect of probiotics on health-related quality of life (Studies II, IV)
Th e mean RAND-36 HRQOL scores in IBS patients at baseline compared to the scores in the 
general Finnish population (Aalto et al. 1999) appear in Figure 8. IBS patients have lower scores 
for physical role functioning, pain, general health, energy and social functioning. 
In Study II, there was no eff ect of the probiotic intervention on HRQOL as analysed by the 
mean change of the total HRQOL score, the eight individual scales, the RAND-36 Physical 
Component scale (including physical functioning, role functioning/physical, pain and general 
62
health) and the RAND-36 Mental Component scale (including energy, role functioning/emotional, 
emotional wellbeing and social functioning). 
In Study IV, the IBSQ divided quality of life into four domains: bowel symptoms, fatigue, 
activity limitations and emotional function. Th e probiotic supplementation improved the bowel 
symptoms domain, as the Hodges-Lehmann estimate for median change from baseline to the 
end of the study was 0.62 points (95% CI: 0.37 to 0.86) in the probiotic group versus 0.37 points 
(95% CI: 0.17 to 0.61) in the placebo group (p=0.045). No signifi cant eff ects were seen in the 
other domains.
Figure 8. The baseline HRQOL scores (means with 95% CIs) in IBS patients (Study II; n=101). 
Dotted line shows the scores in the general Finnish population (Aalto et al. 1999) weighted to 
match the age and gender distribution of the study population.
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5.3 Characterisation of probiotic action in IBS
Effect of probiotic supplementation on intestinal microbiota (Studies III, IV)
In Study III, the recovery of the ingested probiotic strains and the counts of altogether 17 bacterial 
groups or species were investigated. All supplemented probiotic strains (LGG, Lc705, PJS, Bb99) 
were detected in faecal samples. Intestinal microbiota remained stable during the trial (Figure 9), 
except for Bifi dobacterium spp., which increased in the placebo group (from 9.19 log10 at baseline 
to 9.76 at three months and to 9.82 at six months), while the counts decreased in the probiotic 
group (from 9.58 to 9.43 and 9.11, respectively) (p for diff erence between groups =0.028). No 
signifi cant changes in SCFAs or bacterial enzyme activities occurred. 
Figure 9. Ratios between the probiotic group (n=22) and the placebo group (n=21) for 
analysed bacterial groups (log10 mean with 95% CI of 3 and 6 month sample). 
In Study IV, the global intestinal microbiota stability was assessed by a similarity index in 20 
patients. Following the introduction of probiotics or placebo, the mean logarithmic similarity 
index between the baseline and the intervention sample (similarity index AB) was 91.8 (SD 
3.1) in the probiotic group, while it was 94.5 (SD 1.3) in the placebo group (p=0.026). During 
the second half of the intervention period, a stabilisation of the microbiota was observed with 
probiotic supplementation, as the similarity index increased with the probiotic supplementation 
(1.87 ± 3.13) and decreased with placebo (-2.93 ± 1.68). Th e diff erence between the groups (-4.8; 
95% CI -6.59 to -2.54) was signifi cant (p=0.0015).
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Effects of probiotic supplementation on systemic inflammatory markers 
(Study IV)
Th e probiotic supplementation had no eff ect on serum sensitive-CRP. Th e ratio of the intervention 
value to the baseline value was 0.91 (95% CI: 0.73 to 1.10) for the probiotic supplementation 
and 1.16 (95% CI: 0.85 to 1.47) for placebo (p=0.21). Cytokines were not statistically analysed 
as such a high percentage of the baseline samples were below the detection limit (interferon-γ: 
64%, tumour necrosis factor-α: 100%, IL-2: 89%, IL-4: 79%, IL-6: 64% and IL-10: 99%). 
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6. DISCUSSION
Gastrointestinal symptoms and gut dysfunction caused by IBS aff ect up to one fi ft h of the adult 
population worldwide. Th e etiopathology of IBS is complex, multifactorial and poorly understood, 
and the effi  cacy of current treatment options is considered limited. Earlier studies propose the 
involvement of intestinal microbiota in the pathophysiology of the condition as well as a benefi cial 
eff ect of certain probiotics in the alleviation of IBS symptoms. However, the eff ects of long-term 
probiotic supplementation are not well-known, and few clinical studies have made an attempt 
to investigate the possible mechanisms of action of the probiotics. 
Th is study investigated pathophysiological factors of IBS by comparing the intestinal 
microbiota composition and the colonic metabolite concentration in patients and healthy controls. 
In addition, the long-term eff ects of multispecies probiotic supplementation on the symptoms 
and quality of life in IBS were studied in randomised, double-blind, placebo-controlled clinical 
trials. In order to characterise the actions of the probiotic, the eff ects of supplementation on 
intestinal microbiota composition, activity and stability as well as on systemic infl ammatory 
markers were also assessed. 
6.1 Methodological considerations
Subjects
IBS patients were recruited from primary health care units by experienced physicians. It is advisable 
to recruit patients broadly and to note if the subjects are from primary, secondary or tertiary care 
(Irvine et al. 2006) since signifi cant diff erences in treatment response may exist between primary 
and referred patients (Jones 1999; Longstreth et al. 2001). Consequently, the treatment results 
from this study can be considered applicable to primary health care patients, and possibly non-
consulting community patients, since these groups are fairly similar with regards to symptom 
severity and psychosocial factors (Ringström et al. 2007). However, there are no data indicating 
that the pathophysiology of IBS would diff er amongst patients in diff erent health care settings, 
and the results on pathophysiological factors of IBS could thus have a broader applicability 
among patients. It is noteworthy that the fact that all patients had undergone endoscopy may have 
introduced a slight bias to the study population since endoscopy is not recommended routinely 
as part of IBS diagnosis. In Finland, an endoscopy investigation is recommended in severe 
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diarrhoea, and in other cases its need should be evaluated on a case-by-case basis (Silvennoinen 
2002). All subjects fulfi lled the Rome criteria for IBS, and the number of patients needed for 
the clinical trials (Study II, IV) was based on statistical power calculations, which is in line with 
current recommendations for trials in IBS (Irvine et al. 2006). Th e number of patients in the 
interventions can be considered good in comparison to other interventions within the fi eld of 
probiotics and IBS. Th e majority (83%) of patients studied were women, which may refl ect the 
higher prevalence of IBS in women (for review, see Chang and Heitkemper 2002) or the fact 
that women in general are more prone to seek medical advice for any health problems (Bertakis 
et al. 2000). Th e biased gender distribution made it unfeasible to conduct meaningful subgroup 
analyses. Had it been possible, it would have been valuable to analyse the data separately for men 
and women since gender diff erences in the therapeutic benefi t to serotonergic agents have been 
observed in IBS (Cremonini et al. 2003). 
Healthy subjects were recruited as controls in Studies I and IV. Th e subjects in Study I were 
age- and gender-matched with the patients. Due to ethical issues, the controls in Study V had 
to be patients referred to colonoscopy for specifi c clinical reasons, but otherwise as healthy as 
possible. Subjects with previous intestinal polyps (more than three years since previous fi nding) 
or subjects referred to endoscopy due to anaemia were chosen as eligible controls. Overall, it was 
considered that the controls represented well the general, healthy adult population.
Study designs
Th e clinical trials were conducted as double-blind, randomised, placebo-controlled studies, 
which is the recommended trial design in IBS (Irvine et al. 2006). Th e exceptionally high placebo 
response, estimated to vary between 16 and 71% (Patel et al. 2005), renders the placebo treatment 
arm essential in all IBS trials. Th e current guidelines diff erentiate between short-term studies with 
a minimum treatment of four weeks, and long-term studies lasting at least six months (Irvine et 
al. 2006). Long-term trials should be employed when chronic use of the compound studied is 
anticipated. Both interventions (II, IV) in the current study are clearly of longer duration than 
the majority of interventions on probiotics in IBS since most other trials have been on average 
four to eight weeks long (Nobaek et al. 2000; O’Sullivan and O’Morain 2000; Niedzielin et al. 
2001; Sen et al. 2002; O’Mahony et al. 2005; Whorwell et al. 2006). 
Selection of probiotic strains
In the clinical trials, a multispecies probiotic comprising LGG, Lc705, PJS and Bb99 (II) or Bb12 
(IV) was administered. LGG is considered the most studied probiotic strain worldwide, and its 
benefi cial eff ects in certain GI disturbances, particularly antibiotic-associated diarrhoea and 
rotavirus diarrhoea, are well-documented (Huang et al. 2002). However, previous studies show 
that LGG alone is not particularly successful in alleviating the IBS symptom complex (O’Sullivan 
and O’Morain 2000; Bausserman and Michail 2005; Gawrońska et al. 2007). No single deviance 
has been identifi ed in IBS microbiota, but alterations in microbiota composition and some degree 
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of microbial imbalance appear to be characteristic of IBS (Mättö et al. 2005; Maukonen et al. 
2006; Kassinen et al. 2007). Th is observation combined with the complexity and heterogeneity 
of IBS gave rise to the hypothesis that a multispecies combination may be more effi  cient than a 
single strain. Among the pathophysiological factors of IBS, a dysregulation of peripheral cytokine 
production and typically a low secretion of IL-10 have been shown (O’Mahony et al. 2005). 
Probiotic strains diff er in their immunological eff ects, and Bb99, Bb12 and PJS are relatively 
high inducers of IL-10 production in vitro (Kekkonen et al. 2007). Antimicrobial properties may 
also be of importance in IBS, and inhibition of pathogen adhesion has been shown for all strains 
administered (Collado et al. 2007a), while LGG, Lc705 and PJS additionally have antagonising 
eff ects against yeasts (Suomalainen and Mäyrä-Mäkinen 1999; Hatakka et al. 2007). It should 
be remembered that the role of GI yeast in IBS has not been extensively studied, but one study 
suggests equal levels and prevalence of yeast in IBS patients and control subjects (Mättö et al. 2005). 
Part of the superiority of multispecies probiotics in certain conditions may be due to synergistic 
eff ects between the strains. Especially adhesion can be remarkably modulated by synergism, and 
the presence of LGG has been shown to more than double the adhesion of Bb12 and certain 
P. freudenreichii strains (Ouwehand et al. 2000; Ouwehand et al. 2002b). Regardless of several 
putatively benefi cial attributes of multispecies probiotics, their use is not without limitation. 
Supplementing several strains in a combination makes it impossible to fi nd out whether only 
some of these strains actually account for the observed health eff ects. In order to overcome this, 
trials should optimally include a group receiving the complete multispecies, groups getting each 
strain alone and groups getting combinations of two to three strains. In practice, this is not feasible 
in clinical trials. Furthermore, combining strains could also result in unwanted antagonistic 
eff ects. As an example, the adhesion of Bb99 is reduced when it is used in combination with 
other strains (LGG, Lc705, PJS), whereas the adhesion of the other strains is favourably aff ected 
by the combination (Collado et al. 2007b). Another inadequacy of the present study is that two 
diff erent strains of Bifi dobacterium were used. However, based on in vitro studies, Bb99 and Bb12 
trigger a similar pattern of cytokines (Kekkonen et al. 2007). 
Questionnaires
A similar IBS symptom diary was used in Studies II and IV. Th e diary was developed by the 
research group in Study II, based on our group’s previous questionnaires on GI symptom 
monitoring and on the literature, and it was pre-tested in healthy volunteers. An advantage of this 
was that precisely the same diary was used in Studies II and IV, enabling a comparison between 
the two trials. Validated measurement instruments are recommended, but the lack of validated 
questionnaires has, on the other hand, been a recognised drawback in several IBS studies (Irvine 
et al. 2006), including the current one. Paper diaries in general also suff er from recall bias as a 
substantial proportion of diary entries are made retrospectively (Stone et al. 2002). Electronic 
diaries are one option to overcome this shortcoming, and we have earlier shown that an electronic 
diary correlates well with a paper diary in GI symptom monitoring (Kajander et al. 2007). Th e 
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applied HRQOL surveys were freely available, published questionnaires. Th e RAND 36-Item 
Health Survey (Hays et al. 1993) in Study II is a well-tested and validated questionnaire that is 
used extensively around the world as a tool for assessing generic HRQOL. Th e IBSQ (Wong et 
al. 1998) used in Study IV is an IBS-specifi c questionnaire developed using standard methods, 
but with no reported data on construct validity as yet. Th e food-frequency questionnaire used 
in Study II was developed by our research group and pre-tested in healthy volunteers. 
Microbiological and biochemical analysis
Quantitative PCR, a widely used microbiological detection method based on the quantity of 
bacterial DNA present in a sample, was applied in Studies I and III. PCR-based techniques are 
considered powerful tools for examining the microbial diversity of mixed populations (for review, 
see Furrie 2006). In Study IV, a novel high-throughput microarray enabling the simultaneous 
analysis of approximately 1,000 intestinal microbial species was used (Rajilić-Stojanović 2007). Th e 
HITChip allows relative quantifi cation of microbial groups, and the results obtained with the chip 
have been found to correlate fairly well with FISH and denaturing gradient gel electrophoresis. 
An advantage of the HITChip over qPCR is that no pre-selection of bacterial species or groups 
to be analysed needs to be done. However, only the samples of a subgroup (n=20) were analysed 
by the microarray, and consequently the fi ndings should be interpreted with caution. 
SCFAs, bacterial enzymes and serum CRP were analysed using well-established methods. Th e 
serum cytokines were analysed with the cytometric bead array Th 1/Th 2 kit, which turned out to 
be inappropriate for the current study as the great majority of samples were below the detection 
limit. Th e method is considered highly sensitive, and studies in e.g. allergic infants have found the 
method useful (Viljanen et al. 2005a), even though part of the samples were below the detection 
limit in that population, too. Mucosal metabolites were investigated by two high-throughput 
metabolomic platforms, UPLC/MS-based lipidomics and GCxGC-TOF-based metabolomics. 
Metabolomics is a rapidly developing tool, the sensitivity of which is considered high (for review, 
see Schnackenberg and Beger 2006). One evident shortcoming with metabolomics is that a major 
part of spectral peaks are still unidentifi ed. 
To summarise, the methods used in the current study are considered to be of good quality, 
to be suitable for the study settings, and to comply with current recommendations. 
A wide range of diverse methods have been applied, and novel methods have been 
utilised in parallel with well-established techniques. As for the clinical trials, the 
durations of the interventions are long, and the number of patients included can be 
considered sufﬁ cient. The studies investigating the pathophysiology of IBS may have 
gained from having had larger study populations. 
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6.2 Pathophysiological factors 
Alterations in intestinal microbiota in IBS patients vs. healthy controls
Th e fi ndings of this study are in agreement with previous suggestions of an aberrant microbiota 
in IBS. Quantitative diff erences were seen in the B. catenulatum and the C. coccoides groups, 
both of which were reduced in IBS patients. Moreover, the numbers of lactobacilli were lower 
in the diarrhoea subgroup vs. the constipation group, whereas Veillonella spp. were increased 
in the constipation subgroup compared to the controls. Earlier data on bifi dobacteria in IBS are 
confl icting since both reduced numbers of total bifi dobacteria (Balsari et al. 1982) and levels similar 
to healthy controls have been reported (Mättö et al. 2005). Concerning lactobacilli, our fi ndings 
appear to be in line those of Balsari et al. (1982), who reported lower counts for IBS patients as 
a group. However, it should be taken into consideration that these earlier studies utilised culture 
methods instead of molecular DNA-based methods, which makes direct comparison of results 
diffi  cult. To date, no other studies besides the current one have used qPCR for investigating 
microbiota composition in IBS patients and healthy controls. It is important to highlight that it 
remains unknown whether the microbiota alterations are a cause of IBS or a result of disturbed 
GI function. Recent studies have revealed that commensal bacteria are relevant for normal gut 
function (for review, see Barbara et al. 2005), and GI symptoms caused by a disruption in microbiota 
are a common adverse eff ect of antibiotic treatment (for review, see Coté and Buchman 2006). 
Th ese observations provide support for the hypothesis that microbiota in general could play a 
role in IBS symptom generation. Little is yet known about the clinical relevance of individual 
microbial groups or species on GI health and function, and it is therefore not possible to evaluate 
the functional consequences of specifi c alterations in microbiota composition.
Differences in the mucosal metabolic profile in IBS patients vs. healthy 
controls
Th is study is the fi rst one to examine global diff erences in colonic mucosal metabolite concentrations 
in IBS. Th e most prominent fi nding was an upregulation of various lipid species, particularly 
lysophosphatidylcholines and ceramides, in IBS patients. No similar fi ndings have been reported 
previously, but interestingly, these molecules or the enzymes involved in their formation have been 
associated with IBD (Minami et al. 1994; Haapamäki et al. 1999; Homaidan et al. 2002; Sakata 
et al. 2007). Th e biological relevance of lysophosphatidylcholines and ceramides in intestinal 
dysfunction appears to lie in their potential to impair the mucosal barrier (Karlqvist et al. 1986; 
Otamiri et al. 1986; Sawai et al. 2002) and to enhance pain sensitivity (for reviews, see Malan 
and Porreca 2005; Park and Vasko 2005). Th ese lipids participate in the transmission of noxious 
sensory signals by interacting with various receptor systems, but the exact cellular mechanisms 
behind this remain unknown. As both permeability defects and visceral pain are central to IBS (for 
review, see Drossman 2006), it is reasonable to hypothesise that the upregulation of lipid species 
observed in the current study may be of clinical relevance in IBS pathophysiology. Concerning 
lipids and IBS, it also appears that plasma fatty acid and cholesterol profi les may be disrupted 
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in IBS (Kilkens et al. 2004a). Th e relevance of the fi ndings on non-lipid soluble metabolites is, 
in contrast, more diffi  cult to grasp. IBS cases and controls were fairly well separated into two 
distinct groups, but the function of the molecules that contributed the most to the separation 
in the GI tract is not well established. Similar to a previous experimental study in IBS (Martin 
et al. 2006), elevated levels of creatinine were observed in the IBS group, which may be a sign of 
increased energy consumption and muscle contractility (Clark 1994). Furthermore, it is worth 
noticing that the sample size for the metabolomics study was limited, which implies that the results 
should be interpreted with extra caution. Overall, it may be that the relevance of a single identifi ed 
biomarker is not particularly high, while a systematic up- or down-regulation of a certain group 
of molecules, such as lipids in the current study, could indicate a relevant metabolite type.
Taken together, intestinal microbiota composition is different in individuals with 
IBS in comparison to healthy volunteers. Particularly the B. catenulatum and the C. 
coccoides groups are reduced in IBS, but the biological signiﬁ cance of this ﬁ nding 
remains unclear. The mucosal metabolic proﬁ le in IBS differs from that in healthy 
controls with regard to both lipid- and water-soluble metabolites. The most prominent 
ﬁ nding of colonic mucosa from IBS patients is an upregulation of a number of lipid 
species.
6.3 The effect of probiotic supplementation in IBS
Effect on IBS symptoms
Th e multispecies probiotic supplementation signifi cantly alleviated the primary outcome measure, 
the total IBS score. Th e IBS score, which incorporates both the frequency and the severity of 
symptoms, was reduced by approximately 40% with the probiotic supplementation and by less 
than 10% with placebo supplementation. According to recent guidelines on clinical trial design 
in functional gastrointestinal disorders (Corazziari et al. 2003; Irvine et al. 2006), global symptom 
measures that integrate IBS symptoms into a single numerical index are one of the recommended 
outcomes. Th ere is no consensus on what constitutes a clinically meaningful improvement for 
IBS, but an approximately 50% improvement in the primary endpoint has been suggested as a 
reasonable defi nition of a responder and a 10-15% improvement of the global outcome measure 
over placebo as a clinically signifi cant therapeutic gain (Corazziari et al. 2003). Based on these 
recommendations, the improvement over placebo in the current study is evidently clinically 
relevant, while the improvement in primary endpoint does not entirely reach an improvement of 
50%. However, large variations in the responder defi nition occur, and some studies on alosetron 
and tegaserod have accepted as little as a 10% improvement in a visual analogue scale (Bardhan et 
al. 2000) or one step on a seven-step scale (Tack et al. 2005) as clinically relevant. Th ough several 
trials on IBS and probiotics report a statistically signifi cant eff ect on a global symptom score, on 
individual symptoms or on adequate/satisfactory relief of symptoms, the use of diff erent symptom 
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questionnaires, outcome measures and responder defi nitions makes it challenging to compare 
these results with the ones from the current study. Th e use of “adequate relief of abdominal pain 
and discomfort” or “satisfactory relief of IBS symptoms” as primary outcome measures have 
gained popularity during the last few years (Irvine et al. 2006), and their use in future probiotic 
trials would ensure better comparability between trials. Even though the eff ects of probiotics 
on certain types of diarrhoea are well-established, no eff ects on stool frequency or consistency 
were seen in the present study. Th is may not be unique to the multispecies probiotic since other 
studies that show benefi cial eff ects with probiotic administration have equally failed to see an 
eff ect on bowel habits (Kim et al. 2003; Kim et al. 2005b; O’Mahony et al. 2005).
Effect on quality of life
Th e integration of HRQOL monitoring into treatment trials for IBS is strongly encouraged (Irvine 
et al. 2006). In Study II, no eff ect on quality of life was seen as assessed by the generic RAND-36 
survey (Hays et al. 1993). It may be that the extent of symptom reduction was not considerable 
enough to trigger improvements in HRQOL. Alternatively, it could be that the generic questionnaire 
was unable to detect those HRQOL aspects that are of particular importance in IBS. However, the 
utilisation of the generic questionnaire made it possible to compare the scores for the IBS patients 
with Finnish population values. HRQOL in Finnish IBS patients has not been previously reported, 
and the current data show that quality of life is below population values for several scales in IBS 
patients, which is in line with international data (Hahn et al. 1999; Gralnek et al. 2000; Amouretti 
et al. 2006). In Study IV, the employment of the IBSQ (Wong et al. 1998) revealed an improvement 
of the bowel symptoms domain for the probiotic supplementation vs. placebo. Th e authors of the 
IBSQ have predefi ned a mean change of 0.5 on the 1 to 7 scale as a minimal important change. 
Th e present study demonstrated a change of 0.62 points in the probiotic group, but it should be 
noted that this was based on median, not mean, values. Few studies on IBS and probiotics have 
incorporated HRQOL measures. Bifi dobacterium infantis 35624 has shown signifi cant favourable 
eff ects on IBS symptoms in two studies, whereas concomitant improvement of HRQOL was seen 
in one study (O’Mahony et al. 2005) and unchanged HRQOL in another study (Whorwell et al. 
2006). Another Bifi dobacterium strain has been associated with improvement in comparison to 
placebo in the HRQOL discomfort score (Guyonnet et al. 2007). 
To summarise, the multispecies probiotic alleviates the primary symptoms of IBS 
without affecting bowel habit or characteristics. The probiotic supplementation 
causes an approximately 40% reduction in the total IBS score, whereas the placebo 
has an effect of less than 10%. Generic HRQOL is not affected by probiotic treatment, 
but an IBS-speciﬁ c domain describing bowel symptoms is positively inﬂ uenced by 
the supplementation.
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6.4 Characterisation of probiotic action in IBS
Modification of microbiota
Th e individual strains of the multispecies could all be detected in faecal samples in Study III. No 
other major modifi cations of microbiota or its metabolism, apart from an unexpected decrease 
in bifi dobacteria in the probiotic group, could be seen. Th e probiotic strains were analysed by 
strain-specifi c qPCR assays, and as this method may also detect nonviable bacteria (Huijsdens 
et al. 2002), its usefulness in monitoring probiotic survival may be questioned. Th ough qPCR 
in general tends to give higher bacterial counts than cultivation, the two methods have been 
proven to correlate fairly well (Requena et al. 2002). Our fi ndings are strengthened by an earlier 
cultivation-based study showing the survival of the strains in the GI tract (Viljanen et al. 2005b). 
It remains unclear why Bifi dobacterium spp. were reduced in the probiotic group and increased in 
the placebo group. Supplementation with bifi dobacteria has generally led to an increased (Link-
Amster et al. 1994; Bouhnik et al. 1996) or unchanged (Amann et al. 1998) level of the genus in 
faecal samples. It appeared that only those with originally high counts of Bifi dobacterium spp. 
were the ones who suff ered the decrease. It can be hypothesised that the individuals harbouring 
signifi cant levels may be more susceptible to temporal variations in bacterial counts, or that 
competitive inhibition between the ingested and intestinal bifi dobacteria may have occurred. 
Besides a qPCR-based approach, the eff ects of probiotic supplementation on microbiota were 
analysed by a microarray method in Study IV. Instead of looking at each of the approximately 
1,000 species on the array separately, a similarity index incorporating the information on all 
the probes was used. Th is novel approach shows, for the fi rst time to our knowledge, a general 
stabilisation of the microbiota by probiotic supplementation. Th e fi nding should yet be considered 
preliminary, since the number of patients analysed was restricted. An overall stabilisation of 
the microbiota may have clinical relevance particularly in IBS as these patients may experience 
temporal instability of the microbiota (Mättö et al. 2005; Maukonen et al. 2006). 
Immunomodulation
Th e hypothesis for immunomodulation as one mechanism behind probiotic eff ects in IBS 
relies on data showing systemic and mucosal immune activation in IBS (Dunlop et al. 2003b; 
O’Mahony et al. 2005; Barbara et al. 2007; Liebregts et al. 2007b) and on studies demonstrating 
immunomodulatory eff ects of probiotics (for review, see Ezendam and van Loveren 2006). Th e 
current study failed, however, to see any eff ects of the probiotic supplementation on serum 
sensitive-CRP, and the eff ects on serum cytokines remained unclear. Th e majority of samples 
presented cytokine levels below the detection limit as measured by a cytometric bead array, but 
it cannot be entirely ruled out that the probiotic may still infl uence the cytokine profi le if another 
methodology is used. Only one previous study has incorporated the measurement of an immune 
marker into a clinical trial on probiotics and IBS (O’Mahony et al. 2005). By using PBMCs, this 
study demonstrated a normalisation of an initially elevated IL-10/IL-12 ratio following ingestion 
of B. infantis 35624. CRP could prove to be an interesting marker for probiotic eff ects, since one 
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study in atopic infants indicates modulation of CRP by LGG alone, but not with a multispecies 
probiotic (Viljanen et al. 2005a). In contrast, two other studies on L. plantarum 299v have not 
seen any eff ect on CRP in critically ill patients or in surgical patients (McNaught et al. 2002; 
McNaught et al. 2005). It may be that the mucosal immune system is more relevant than the 
systemic one when the action of probiotics in IBS is being considered.
As a whole, this study provides data showing a stabilisation of the microbiota of IBS 
patients by probiotic supplementation. The stabilisation occurred simultaneously with 
symptom alleviation, and it could at least partly explain the reduced GI symptoms. The 
precise bacterial groups or species accounting for the stabilisation require further 
characterisation. This study does not provide support for the idea that systemic 
immunomodulation is associated with IBS symptom reduction. 
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7. SUMMARY AND CONCLUSIONS 
Th e present study investigated pathophysiological factors of IBS and the eff ect of multispecies 
probiotic supplementation on GI symptoms, health-related quality of life, intestinal microbiota 
and systemic immune markers in IBS. Th e main fi ndings of this study can be summarised as 
follows:
Th e intestinal microbiota composition and the mucosal metabolite profi le are altered in IBS  ?
patients in comparison to healthy subjects. Management regimens aiming at modulating 
these pathophysiological fi ndings could hence be of value in IBS. 
Multispecies probiotic supplementation with  ? L. rhamnosus GG, L. rhamnosus Lc705, P. 
freudenreichii subsp. shermanii JS, and a Bifi dobacterium signifi cantly alleviates the primary 
symptoms of IBS and appears to improve the bowel symptoms domain of quality of life. 
Th e multispecies probiotic can be recommended in mild to moderate cases of IBS as an 
adjunct therapy to lifestyle modifi cation and possible pharmacotherapy.
Probiotic supplementation stabilises the intestinal microbiota in IBS, suggesting that the  ?
favourable eff ects of the probiotics may partly be mediated via mechanisms related to the 
microbiota. Th e results do not support systemic immunomodulation as a mechanism in 
symptom reduction.
Based on this study, subjective symptom recording and monitoring of health-related  ?
quality of life remain the main end-points of clinical trials in IBS, and laboratory tests 
are of only modest, incremental value.
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